https://biolegacyresearch.com/fda-addresses-generic-drug-crl-responses-orange-book-questions-in-new-final-guidances/ 2022-07-25T04:01:00+00:00 https://biolegacyresearch.com/continuing-its-aduhelm-draw-down-biogen-writes-off-275-million-in-inventory/ 2022-07-25T22:39:00+00:00 https://biolegacyresearch.com/fdas-new-real-time-review-aims-to-speed-new-cancer-drugs-to-market/ 2022-07-25T22:40:55+00:00 https://biolegacyresearch.com/icmra-seeks-global-harmony-on-real-world-data/ 2022-07-25T22:42:27+00:00 https://biolegacyresearch.com/clinical-researcher-likely-to-be-nominated-to-lead-the-national-cancer-institute/ 2022-07-25T22:43:36+00:00 https://biolegacyresearch.com/ema-expert-panel-greenlights-11-new-drugs/ 2022-07-25T22:46:24+00:00 https://biolegacyresearch.com/booker-paul-introduce-senate-right-to-try-bill-for-mdma-and-psilocybin/ 2022-07-26T21:49:26+00:00 https://biolegacyresearch.com/fda-gives-priority-review-to-biogens-tofersen-for-rare-form-of-als/ 2022-07-26T21:57:43+00:00 https://biolegacyresearch.com/federal-court-rules-against-two-pfizer-copay-plans-citing-anti-kickback-statute/ 2022-07-26T23:05:26+00:00 https://biolegacyresearch.com/episciences-gets-form-483-for-lack-of-testing-deficient-cleaning-procedures/ 2022-07-26T23:07:20+00:00 https://biolegacyresearch.com/sandoz-makes-u-s-european-headway-with-first-tysabri-biosimilar/ 2022-07-28T04:01:00+00:00 https://biolegacyresearch.com/teva-pharmaceuticals-agrees-to-4-25-billion-settlement-of-opioid-claims/ 2022-07-28T04:01:00+00:00 https://biolegacyresearch.com/avadel-sues-fda-claiming-botched-approval-process-for-narcolepsy-drug-lumryz/ 2022-07-28T04:01:00+00:00 https://biolegacyresearch.com/fda-slaps-bi-coastal-pharma-for-complaint-handling-qa-problems/ 2022-07-28T04:01:00+00:00 https://biolegacyresearch.com/teva-settlement-sets-2-billion-price-tag-for-allergan-opioid-lawsuits/ 2022-07-28T22:53:25+00:00 https://biolegacyresearch.com/chemo-combo-racks-up-positive-early-phase-data-for-urothelial-cancer/ 2022-07-28T22:54:28+00:00 https://biolegacyresearch.com/german-biotech-inflarx-will-seek-eua-for-new-covid-19-antibody/ 2022-07-28T22:55:30+00:00 https://biolegacyresearch.com/vertex-widens-patent-battle-against-lupin-over-cystic-fibrosis-drug/ 2022-07-28T22:56:30+00:00 https://biolegacyresearch.com/api-manufacturer-draws-warning-letter-for-investigation-cleaning-lapses/ 2022-07-28T22:57:34+00:00 https://biolegacyresearch.com/user-fees-in-the-balance/ 2022-07-29T22:56:34+00:00 https://biolegacyresearch.com/bristol-myers-squibbs-checkmate-combo-regimen-fails-in-renal-cell-cancer/ 2022-07-29T22:58:41+00:00 https://biolegacyresearch.com/fda-lifts-clinical-hold-on-editas-gene-editing-therapy-in-sickle-cell-disease/ 2022-07-29T23:03:39+00:00 https://biolegacyresearch.com/gene-therapy-manufacturing-best-practices-explored-in-project-a-cell-paper/ 2022-07-29T23:04:54+00:00 https://biolegacyresearch.com/astrazeneca-ends-phase-3-study-on-immunotherapy-in-head-and-neck-cancer/ 2022-08-01T21:24:19+00:00 https://biolegacyresearch.com/obseva-scraps-plans-for-uterine-fibroid-candidate/ 2022-08-01T21:25:35+00:00 https://biolegacyresearch.com/sanofi-loses-appeal-against-viatris-over-alleged-epipen-monopoly/ 2022-08-01T21:26:42+00:00 https://biolegacyresearch.com/biktarvy-suppresses-hiv-infections-for-five-years-with-no-treatment-failure/ 2022-08-02T22:17:28+00:00 https://biolegacyresearch.com/west-virginia-accepts-400m-opioid-settlement-from-drug-distributors/ 2022-08-02T22:18:41+00:00 https://biolegacyresearch.com/jj-files-arbitration-demand-in-emergent-dispute/ 2022-08-02T22:20:28+00:00 https://biolegacyresearch.com/fda-to-open-faers-to-expedited-safety-reports-from-ba-be-studies/ 2022-08-02T22:35:37+00:00 https://biolegacyresearch.com/appeals-court-sides-with-abbvie-in-humira-patent-thicket-antitrust-suit/ 2022-08-04T04:01:00+00:00 https://biolegacyresearch.com/fda-green-lights-cimerli-as-the-first-interchangeable-biosimilar-to-lucentis/ 2022-08-04T04:01:00+00:00 https://biolegacyresearch.com/alnylam-claims-success-with-phase-3-results-of-cardiomyopathy-drug-patisiran/ 2022-08-04T04:01:00+00:00 https://biolegacyresearch.com/keytruda-lenvima-combo-fails-in-liver-cancer-study/ 2022-08-04T04:01:00+00:00 https://biolegacyresearch.com/amgen-to-buy-chemocentryx-gaining-first-in-class-inflammation-drug/ 2022-08-04T21:37:48+00:00 https://biolegacyresearch.com/eli-lilly-must-pay-61-million-penalty-for-underpayment-of-medicaid-rebates/ 2022-08-04T21:38:50+00:00 https://biolegacyresearch.com/pfizer-drops-array-cardiology-candidate-after-negative-interim-results/ 2022-08-04T21:40:09+00:00 https://biolegacyresearch.com/woodcock-stresses-dire-need-for-user-fees-reauthorization-data-modernization/ 2022-08-04T22:21:44+00:00 https://biolegacyresearch.com/astrazeneca-bristol-myers-squibb-and-mckesson-diabetes-drug-case-dismissed/ 2022-08-05T22:11:53+00:00 https://biolegacyresearch.com/fda-seeks-additional-trial-for-acadias-nuplazid-alzheimers-snda/ 2022-08-05T22:23:55+00:00 https://biolegacyresearch.com/senate-set-to-pass-historic-drug-pricing-bill/ 2022-08-05T22:33:49+00:00 https://biolegacyresearch.com/california-otc-drugmaker-draws-fda-warning-for-repeated-lapses-unapproved-drugs/ 2022-08-05T22:35:46+00:00 https://biolegacyresearch.com/senate-passes-historic-drug-pricing-bill/ 2022-08-07T04:01:00+00:00 https://biolegacyresearch.com/phrma-lashes-out-against-senate-bill-allowing-medicare-to-negotiate-drug-prices/ 2022-08-09T04:01:00+00:00 https://biolegacyresearch.com/pfizer-to-purchase-sickle-cell-drugmaker-global-blood-therapeutics/ 2022-08-09T04:01:00+00:00 https://biolegacyresearch.com/fda-approves-first-targeted-therapy-for-her2-low-breast-cancer-2/ 2022-08-09T04:01:00+00:00 https://biolegacyresearch.com/patient-data-from-many-cancer-trials-inaccessible-to-drug-researchers-study-finds/ 2022-08-09T04:01:00+00:00 https://biolegacyresearch.com/court-says-pfizers-copays-for-heart-drug-may-violate-anti-kickback-law/ 2022-08-09T22:23:22+00:00 https://biolegacyresearch.com/sugemalimab-confers-progression-free-survival-benefit-in-nsclc/ 2022-08-09T22:25:23+00:00 https://biolegacyresearch.com/regeneron-alleges-viatris-biosimilar-infringes-on-eylea/ 2022-08-09T22:26:39+00:00 https://biolegacyresearch.com/karuna-unveils-positive-phase-3-data-for-potential-first-in-class-antipsychotic/ 2022-08-09T22:28:35+00:00 https://biolegacyresearch.com/gsk-and-mersana-unite-in-collaboration-deal-potentially-worth-1-4b/ 2022-08-10T21:48:53+00:00 https://biolegacyresearch.com/positive-phase-3-data-could-net-verona-pharma-a-first-in-class-copd-treatment/ 2022-08-10T21:50:22+00:00 https://biolegacyresearch.com/fda-expert-panel-to-review-first-fecal-microbiota-transplant/ 2022-08-10T21:54:02+00:00 https://biolegacyresearch.com/epipen-lawsuit-against-mylan-proceeds-as-pfizer-wins-motion-to-dismiss/ 2022-08-10T22:07:35+00:00 https://biolegacyresearch.com/topline-data-show-benefit-of-abecma-in-relapsed-multiple-myeloma/ 2022-08-11T21:55:54+00:00 https://biolegacyresearch.com/tislelizmab-topline-data-scores-in-liver-cancer-trial/ 2022-08-11T21:57:39+00:00 https://biolegacyresearch.com/akorn-draws-fda-form-483-over-unexplained-discrepancies-batch-failures/ 2022-08-11T21:59:10+00:00 https://biolegacyresearch.com/catalent-to-acquire-cdmo-metrics-contract-services-for-475-million/ 2022-08-11T22:13:33+00:00 https://biolegacyresearch.com/135-million-more-emergent-covid-19-vaccine-doses-must-be-trashed-say-lawmakers/ 2022-08-12T22:11:24+00:00 https://biolegacyresearch.com/risk-information-in-promotional-tweets-better-than-links-fda-study-shows/ 2022-08-12T22:12:00+00:00 https://biolegacyresearch.com/monkeypox-vaccine-data-dont-support-fda-administration-recommendations-maker-says/ 2022-08-12T22:42:06+00:00 https://biolegacyresearch.com/house-passes-landmark-bill-allowing-u-s-to-negotiate-drug-prices-for-medicare/ 2022-08-12T23:10:21+00:00 https://biolegacyresearch.com/brainstorm-counting-on-new-subanalysis-for-als-treatment/ 2022-08-16T04:01:00+00:00 https://biolegacyresearch.com/illinois-tool-works-given-a-form-483-for-old-and-new-issues/ 2022-08-16T04:01:00+00:00 https://biolegacyresearch.com/enhertu-sees-more-success-with-another-phase-3-trial-win-in-breast-cancer/ 2022-08-16T04:01:00+00:00 https://biolegacyresearch.com/novartis-calls-third-strike-for-ilaris-in-lung-cancer/ 2022-08-16T04:01:00+00:00 https://biolegacyresearch.com/trodelvy-hits-key-secondary-endpoint-in-breast-cancer-trial/ 2022-08-16T22:00:40+00:00 https://biolegacyresearch.com/merck-and-orna-partner-on-circular-rna-approach-to-vaccines-cancer-treatments/ 2022-08-16T22:01:45+00:00 https://biolegacyresearch.com/fda-technical-guide-gives-u-s-specific-instructions-for-electronic-icsr-submission/ 2022-08-16T22:03:00+00:00 https://biolegacyresearch.com/emergents-woes-continue-as-fda-warning-letter-cites-poor-management-oversight/ 2022-08-16T23:15:31+00:00 https://biolegacyresearch.com/disappointing-phase-3-data-closes-sanofis-book-on-amcenestrant/ 2022-08-17T22:05:23+00:00 https://biolegacyresearch.com/fda-approves-bluebird-bios-zynteglo-for-beta-thalassemia/ 2022-08-17T22:06:22+00:00 https://biolegacyresearch.com/blueprint-will-seek-supplemental-approval-for-avyakit/ 2022-08-17T22:07:11+00:00 https://biolegacyresearch.com/no-testing-inadequate-cleaning-land-verde-cosmetics-an-fda-warning-letter/ 2022-08-17T22:07:59+00:00 https://biolegacyresearch.com/gsk-snags-nda-nod-for-myelofibrosis-candidate/ 2022-08-19T04:01:00+00:00 https://biolegacyresearch.com/eton-loses-patent-dispute-to-produce-generic-version-of-exelas-elcys/ 2022-08-19T04:01:00+00:00 https://biolegacyresearch.com/homology-pauses-trial-recruitment-lays-off-staff/ 2022-08-19T04:01:00+00:00 https://biolegacyresearch.com/oig-audit-nih-dropped-the-ball-on-enforcing-trial-reporting-requirements/ 2022-08-19T04:01:00+00:00 https://biolegacyresearch.com/astellas-gets-nda-ok-for-potential-first-in-class-hot-flash-med/ 2022-08-19T22:17:04+00:00 https://biolegacyresearch.com/drug-units-recalled-plunge-in-second-quarter-as-recalls-remain-steady/ 2022-08-19T22:17:26+00:00 https://biolegacyresearch.com/colorado-names-private-sector-partners-for-canadian-drugs-imports/ 2022-08-19T22:18:09+00:00 https://biolegacyresearch.com/australian-biotech-will-seek-approval-for-anti-edema-drug/ 2022-08-19T22:18:47+00:00 https://biolegacyresearch.com/less-than-40-percent-of-drugs-with-accelerated-approval-are-of-high-therapeutic-value/ 2022-08-22T21:18:22+00:00 https://biolegacyresearch.com/fda-updates-draft-guidance-on-charging-for-investigational-drugs-with-additional-advice/ 2022-08-22T21:19:00+00:00 https://biolegacyresearch.com/fda-slaps-sun-pharma-with-form-483-for-allegedly-falsifying-documents/ 2022-08-22T21:20:09+00:00 https://biolegacyresearch.com/vifor-wins-patent-case-against-teva-over-phosphate-controlling-velphoro/ 2022-08-22T21:22:04+00:00 https://biolegacyresearch.com/wockhardt-manufacturing-division-ordered-by-doj-to-shut-down/ 2022-08-23T22:05:38+00:00 https://biolegacyresearch.com/reforms-needed-in-fda-advisory-committee-process-says-former-adcomm-member/ 2022-08-23T22:07:16+00:00 https://biolegacyresearch.com/endo-loses-contested-patent-suit-just-days-after-bankruptcy-filing/ 2022-08-23T22:09:07+00:00 https://biolegacyresearch.com/alcon-snags-aerie-pharmaceuticals-and-its-prescription-eyedrop-portfolio/ 2022-08-23T22:10:51+00:00 https://biolegacyresearch.com/gilead-sciences-cipla-to-face-class-action-lawsuit-over-truvada/ 2022-08-25T04:01:00+00:00 https://biolegacyresearch.com/califf-defends-fda-decisions-calls-for-improved-research-system/ 2022-08-25T04:01:00+00:00 https://biolegacyresearch.com/fda-warns-tramadol-us-to-cease-selling-unapproved-drugs-direct-to-consumers/ 2022-08-25T04:01:00+00:00 https://biolegacyresearch.com/indivior-will-face-federal-jury-over-suboxone-charges/ 2022-08-25T04:01:00+00:00 https://biolegacyresearch.com/pfizer-will-file-bla-for-first-ever-rsv-vaccine/ 2022-08-25T21:19:35+00:00 https://biolegacyresearch.com/u-s-drug-manufacturing-growth-leads-the-world/ 2022-08-25T21:58:57+00:00 https://biolegacyresearch.com/psilocybin-reduces-alcohol-use-study-finds/ 2022-08-25T22:03:00+00:00 https://biolegacyresearch.com/paxlovid-offers-no-benefit-to-the-middle-aged-study-shows/ 2022-08-25T22:08:40+00:00 https://biolegacyresearch.com/novartis-to-spin-off-sandoz-generics-and-biosimilars-division/ 2022-08-25T22:22:21+00:00 https://biolegacyresearch.com/moderna-sues-pfizer-and-biontech-for-patent-infringement-on-covid-19-vaccines/ 2022-08-29T04:01:00+00:00 https://biolegacyresearch.com/eu-releases-much-anticipated-gmp-annex-on-sterile-products/ 2022-08-29T04:01:00+00:00 https://biolegacyresearch.com/fda-endorses-four-draft-and-final-ich-quality-guidelines/ 2022-08-29T04:01:00+00:00 https://biolegacyresearch.com/white-house-orders-federal-agencies-to-publicly-share-research-findings/ 2022-08-29T04:01:00+00:00 https://biolegacyresearch.com/opqs-annual-report-reveals-drop-in-import-alerts-other-quality-metrics/ 2022-08-29T04:01:00+00:00 https://biolegacyresearch.com/califf-says-chronic-illness-health-inequities-should-be-biomedical-priorities/ 2022-08-29T04:01:00+00:00 https://biolegacyresearch.com/farxiga-trials-show-reduced-risk-of-death-and-worsening-heart-failure/ 2022-08-30T04:01:00+00:00 https://biolegacyresearch.com/bayer-racks-kerendia-win-in-subgroup-analysis/ 2022-08-30T04:01:00+00:00 https://biolegacyresearch.com/industry-asks-fda-for-more-time-and-transparency-in-drug-shortage-guidance/ 2022-08-30T04:01:00+00:00 https://biolegacyresearch.com/westwood-laboratories-handed-a-form-483-for-lack-of-sterility-procedures/ 2022-08-30T04:01:00+00:00 https://biolegacyresearch.com/no-financial-incentive-to-complete-confirmatory-trials-for-accelerated-approvals-study-finds/ 2022-08-30T22:00:13+00:00 https://biolegacyresearch.com/two-universities-sue-novartis-over-drug-design-patent/ 2022-08-30T22:00:17+00:00 https://biolegacyresearch.com/neurocrines-bid-for-diurnal-could-snag-phase-3-cah-drug/ 2022-08-30T22:00:20+00:00 https://biolegacyresearch.com/fda-slaps-lupin-with-form-483-for-risk-of-contamination-lack-of-in-process-testing/ 2022-08-30T22:00:25+00:00 https://biolegacyresearch.com/califf-is-bullish-on-newly-authorized-bivalent-covid-19-boosters-ahead-of-data/ 2022-08-31T22:28:25+00:00 https://biolegacyresearch.com/icer-wegovy-superior-to-other-weight-loss-drugs-but-not-cost-effective/ 2022-08-31T22:28:55+00:00 https://biolegacyresearch.com/amgen-claims-win-in-nsclc-with-lumakras/ 2022-08-31T22:29:25+00:00 https://biolegacyresearch.com/green-wave-draws-warning-letter-for-blocking-inspection-testing-and-record-keeping-issues/ 2022-08-31T22:29:57+00:00 https://biolegacyresearch.com/fda-denies-hearing-request-for-intarcias-diabetes-nda/ 2022-09-01T20:43:22+00:00 https://biolegacyresearch.com/desantis-files-suit-against-fda-over-delay-on-prescription-drug-import-plan/ 2022-09-01T21:33:04+00:00 https://biolegacyresearch.com/fda-increased-its-pre-anda-user-fee-funded-activities-in-fiscal-2021/ 2022-09-01T21:55:00+00:00 https://biolegacyresearch.com/novo-nordisk-snags-formas-sickle-cell-candidate-in-1-1-million-deal/ 2022-09-01T22:10:15+00:00 https://biolegacyresearch.com/district-judge-says-fda-doesnt-have-oversight-over-stem-cell-therapy/ 2022-09-01T22:33:32+00:00 https://biolegacyresearch.com/united-therapeutics-wins-one-loses-one-in-tyvaso-patent-dispute/ 2022-09-02T19:22:53+00:00 https://biolegacyresearch.com/potential-product-contamination-lack-of-records-lands-bpi-labs-a-form-483/ 2022-09-02T20:18:00+00:00 https://biolegacyresearch.com/drug-free-topical-gel-could-become-u-s-first-otc-erectile-dysfunction-treatment/ 2022-09-02T20:36:10+00:00 https://biolegacyresearch.com/otsuka-and-h-lundbeck-sue-viatris-over-abilify-maintena-again/ 2022-09-02T20:41:19+00:00 https://biolegacyresearch.com/fda-tepid-on-amylyxs-second-try-for-als-therapy-amx0035/ 2022-09-07T04:01:00+00:00 https://biolegacyresearch.com/analgesic-manufacturer-skyless-hit-with-483-for-absence-of-gmp-procedures-training/ 2022-09-07T04:01:00+00:00 https://biolegacyresearch.com/inspection-findings-at-reykjavik-facility-delay-alvotechs-bla-approval/ 2022-09-07T04:01:00+00:00 https://biolegacyresearch.com/bayer-to-settle-for-40m-in-suits-alleging-kickbacks-and-false-statements/ 2022-09-07T04:01:00+00:00 https://biolegacyresearch.com/fda-lifts-clinical-hold-on-sareptas-duchenne-muscular-dystrophy-drug-candidate/ 2022-09-07T19:34:33+00:00 https://biolegacyresearch.com/ucb-touts-complete-skin-clearance-in-psoriasis-drug-trial/ 2022-09-07T19:34:38+00:00 https://biolegacyresearch.com/y-mabs-gets-another-shot-for-its-liquid-radiation-pediatric-brain-tumor-antibody/ 2022-09-07T21:22:10+00:00 https://biolegacyresearch.com/fda-guidance-describes-pharmacology-considerations-for-pediatric-drug-studies/ 2022-09-07T21:22:59+00:00 https://biolegacyresearch.com/fda-adcomm-votes-7-2-for-amylyxs-als-drug-despite-unfavorable-fda-briefing/ 2022-09-09T04:01:00+00:00 https://biolegacyresearch.com/fda-issues-guidances-on-real-world-data-evidence-submission-and-labeling-issues/ 2022-09-09T04:01:00+00:00 https://biolegacyresearch.com/gilead-hutchmed-unveil-positive-phase-3-oncology-data-at-european-meeting/ 2022-09-09T04:01:00+00:00 https://biolegacyresearch.com/cancer-immunotherapies-become-key-ingredients-in-two-corporate-deals/ 2022-09-09T04:01:00+00:00 https://biolegacyresearch.com/fda-focus-area-report-for-2022-expands-on-oncology-rare-disease-research/ 2022-09-09T21:57:04+00:00 https://biolegacyresearch.com/regeneron-and-bayer-get-positive-results-from-higher-eylea-dosage-trials/ 2022-09-09T21:57:28+00:00 https://biolegacyresearch.com/esmo-a-hit-and-a-miss-for-renal-cell-cancer-and-good-news-for-elderly-with-nsclc/ 2022-09-09T21:58:01+00:00 https://biolegacyresearch.com/more-keytruda-trial-failures-pile-up-despite-multiple-approvals/ 2022-09-09T21:58:33+00:00 https://biolegacyresearch.com/califf-political-pressure-digital-disinformation-undermine-fdas-work/ 2022-09-12T20:09:00+00:00 https://biolegacyresearch.com/biden-inks-executive-order-to-shore-up-domestic-biomanufacturing/ 2022-09-12T21:55:24+00:00 https://biolegacyresearch.com/nih-opens-phase-3-trial-to-test-smallpox-antiviral-on-monkeypox/ 2022-09-12T22:06:19+00:00 https://biolegacyresearch.com/phase-3-round-up-liver-cancer-nsclc-and-hidradenitis-suppurativa-treatments-all-see-strides-made-in-late-stage-research/ 2022-09-12T22:24:54+00:00 https://biolegacyresearch.com/raps-report-recall-response-planning-communication-and-caring-will-build-customer-loyalty-says-expert/ 2022-09-13T20:34:39+00:00 https://biolegacyresearch.com/gilead-settles-five-lawsuits-with-generic-drugmakers-over-descovy-odefsey-and-vemlidy/ 2022-09-13T20:39:00+00:00 https://biolegacyresearch.com/fda-research-shows-three-years-of-generic-approvals-yield-53-3-billion-in-savings/ 2022-09-13T20:39:00+00:00 https://biolegacyresearch.com/raps-report-diversity-in-clinical-trials-remains-an-ongoing-challenge/ 2022-09-13T20:39:00+00:00 https://biolegacyresearch.com/fda-follows-ich-guidelines-in-q3dr2-elemental-impurities-guidance/ 2022-09-15T04:01:00+00:00 https://biolegacyresearch.com/raps-report-real-time-oncology-review-can-knock-two-months-off-approval-wait-new-data-shows/ 2022-09-15T04:01:00+00:00 https://biolegacyresearch.com/omega-delta-gets-form-483-for-water-system-problems-repeat-observations/ 2022-09-15T04:01:00+00:00 https://biolegacyresearch.com/fda-issues-final-rule-on-drug-company-right-to-try-annual-reports/ 2022-09-15T04:01:00+00:00 https://biolegacyresearch.com/federal-judge-again-tosses-kickback-suit-over-novartis-gilenya/ 2022-09-15T04:01:00+00:00 https://biolegacyresearch.com/raps-report-salary-work-life-balance-drive-regulatory-staff-job-changes-in-2021/ 2022-09-16T04:01:00+00:00 https://biolegacyresearch.com/fda-nih-launch-public-private-partnership-for-neurodegenerative-diseases/ 2022-09-16T04:01:00+00:00 https://biolegacyresearch.com/swiss-authorities-conduct-raid-of-novartis-for-alleged-patent-misuse/ 2022-09-16T04:01:00+00:00 https://biolegacyresearch.com/icer-evaluates-cost-effectiveness-of-hemophilia-gene-therapies-als-drugs/ 2022-09-16T04:01:00+00:00 https://biolegacyresearch.com/fda-updates-mapp-procedures-regarding-sges-representing-sponsors-before-cder/ 2022-09-16T04:01:00+00:00 https://biolegacyresearch.com/drugmakers-abuse-outdated-patent-system-to-delay-competition-consumer-group-says/ 2022-09-16T21:31:43+00:00 https://biolegacyresearch.com/emas-human-medicines-committee-endorses-12-new-drugs-at-monthly-meeting/ 2022-09-16T21:32:09+00:00 https://biolegacyresearch.com/phase-3-data-roundup-danicopan-lebrikizumab-opdivo-vacneuvance-15/ 2022-09-16T21:32:35+00:00 https://biolegacyresearch.com/alvotechs-bla-denial-down-to-multiple-quality-failures-form-483-shows/ 2022-09-16T21:46:47+00:00 https://biolegacyresearch.com/congress-still-undecided-on-user-fee-legislation-as-deadline-looms/ 2022-09-18T23:55:05+00:00 https://biolegacyresearch.com/skysona-gene-therapy-snags-accelerated-approval/ 2022-09-19T21:22:38+00:00 https://biolegacyresearch.com/mallinckrodts-terlipressin-wins-fda-approval-after-three-complete-response-letters/ 2022-09-19T21:23:10+00:00 https://biolegacyresearch.com/vanda-takes-third-swing-at-fda-with-suit-claiming-unlawful-delay-in-hearing/ 2022-09-19T21:23:44+00:00 https://biolegacyresearch.com/generic-drugmaker-akorn-to-pay-7-9-million-medicare-fine/ 2022-09-19T21:24:20+00:00 https://biolegacyresearch.com/lawsuits-pile-up-for-gsk-and-others-over-zantacs-potential-cancer-risk/ 2022-09-21T04:01:00+00:00 https://biolegacyresearch.com/amyndas-can-continue-to-battle-zealand-us-over-alleged-violation-of-trade-secrets/ 2022-09-21T04:01:00+00:00 https://biolegacyresearch.com/merck-to-investigate-a-lower-dose-of-its-hiv-drug/ 2022-09-21T04:01:00+00:00 https://biolegacyresearch.com/eu-makes-biosimilars-officially-interchangeable-while-fda-ponders-and-awaits-funds/ 2022-09-21T04:01:00+00:00 https://biolegacyresearch.com/fda-briefs-adcomm-on-high-risk-limited-benefit-of-spectrums-pozenveo/ 2022-09-22T04:01:00+00:00 https://biolegacyresearch.com/fdas-new-overdose-prevention-framework-leaves-many-unanswered-questions/ 2022-09-22T04:01:00+00:00 https://biolegacyresearch.com/catalents-bloomington-facility-rapped-for-multiple-quality-failures/ 2022-09-22T04:01:00+00:00 https://biolegacyresearch.com/fda-provides-guidance-on-securing-samples-for-generics-and-biosilimars/ 2022-09-22T04:01:00+00:00 https://biolegacyresearch.com/fda-clarifies-supply-chain-exemptions-to-speed-delivery-of-approved-naloxone-products/ 2022-09-23T04:01:00+00:00 https://biolegacyresearch.com/senate-ready-to-pass-thin-version-of-user-fee-legislation/ 2022-09-23T04:01:00+00:00 https://biolegacyresearch.com/biolab-sciences-draws-warning-letter-for-marketing-unapproved-biologics/ 2022-09-23T04:01:00+00:00 https://biolegacyresearch.com/cancer-adcomm-votes-no-on-spectrums-pozenveo-for-orphan-disease-lung-cancer/ 2022-09-23T04:01:00+00:00 https://biolegacyresearch.com/advisory-committee-oks-first-fda-regulated-fecal-microbiota-transplant/ 2022-09-23T04:01:00+00:00 https://biolegacyresearch.com/fdas-odac-votes-no-to-cancer-drugs-copiktra-and-pepaxto/ 2022-09-23T21:43:39+00:00 https://biolegacyresearch.com/biogens-als-treatment-shows-some-potential-in-extension-study/ 2022-09-23T21:44:00+00:00 https://biolegacyresearch.com/fda-shares-ethical-trial-design-considerations-for-pediatric-participants/ 2022-09-23T21:44:27+00:00 https://biolegacyresearch.com/problems-with-monitoring-of-aseptic-areas-and-quality-control-lands-cipla-ltd-a-form-483/ 2022-09-23T21:45:05+00:00 https://biolegacyresearch.com/fda-oncology-leaders-sketch-out-new-trial-designs-for-accelerated-approvals/ 2022-09-27T04:01:00+00:00 https://biolegacyresearch.com/eu-seeing-success-in-trial-transparency-but-some-member-nations-holding-back/ 2022-09-27T04:01:00+00:00 https://biolegacyresearch.com/ogd-director-sally-choe-to-exit-fda/ 2022-09-27T04:01:00+00:00 https://biolegacyresearch.com/new-york-facility-hit-with-fda-form-483-for-multiple-lapses/ 2022-09-27T04:01:00+00:00 https://biolegacyresearch.com/congress-to-attach-stripped-down-user-fee-bill-to-cr-this-week/ 2022-09-27T21:45:00+00:00 https://biolegacyresearch.com/biogen-settles-whistleblower-kickback-suit-for-900-million/ 2022-09-27T21:45:24+00:00 https://biolegacyresearch.com/single-adverse-event-nets-clinical-hold-for-aviditys-dm1-study/ 2022-09-27T21:45:27+00:00 https://biolegacyresearch.com/fda-issues-draft-guidance-on-electronic-submission-of-otc-monographs/ 2022-09-27T21:45:30+00:00 https://biolegacyresearch.com/sponsors-seek-more-clarity-in-draft-guidance-on-patient-focused-drug-development/ 2022-09-29T04:01:00+00:00 https://biolegacyresearch.com/lecanemab-biogens-second-antiamyloid-antibody-posts-positive-phase-3-numbers/ 2022-09-29T04:01:00+00:00 https://biolegacyresearch.com/zhejiang-tianyu-receives-fda-warning-letter-over-impurities-batch-deviations/ 2022-09-29T04:01:00+00:00 https://biolegacyresearch.com/cbers-office-of-tissues-and-advanced-therapies-gets-super-office-status-new-name/ 2022-09-29T04:01:00+00:00 https://biolegacyresearch.com/senate-passes-cr-with-clean-user-fee-reauthorization-attached/ 2022-09-29T21:59:38+00:00 https://biolegacyresearch.com/biohavens-als-drug-candidate-disappoints-in-late-stage-study/ 2022-09-29T22:00:07+00:00 https://biolegacyresearch.com/fda-posts-long-awaited-proposed-rules-for-human-subjects-research/ 2022-09-29T22:00:40+00:00 https://biolegacyresearch.com/fda-slaps-german-drugmaker-with-warning-letter-over-validation-problems/ 2022-09-29T22:01:42+00:00 https://biolegacyresearch.com/user-fee-agreements-reauthorized-but-what-about-the-policy-riders/ 2022-10-02T17:28:18+00:00 https://biolegacyresearch.com/amylyxs-als-drug-relyvrio-snags-fda-approval/ 2022-10-02T17:29:05+00:00 https://biolegacyresearch.com/accelerated-approval-drugs-stay-on-market-for-years-without-showing-benefit-hhs-reports/ 2022-10-02T17:29:41+00:00 https://biolegacyresearch.com/ema-safety-committee-calls-for-new-warnings-on-three-drugs-and-drug-combinations/ 2022-10-02T17:30:33+00:00 https://biolegacyresearch.com/guidance-round-up-fda-issues-guidance-on-physical-attributes-of-generics-drug-master-files-and-inspection-readiness/ 2022-10-03T22:06:00+00:00 https://biolegacyresearch.com/califf-fda-launches-external-review-into-fdas-handling-of-approved-opioids/ 2022-10-03T22:06:40+00:00 https://biolegacyresearch.com/eu-should-establish-its-own-priority-review-voucher-system-says-industry-group/ 2022-10-03T22:07:14+00:00 https://biolegacyresearch.com/logicbio-brings-two-gene-editing-platforms-to-astrazeneca-in-68-million-deal/ 2022-10-03T22:07:40+00:00 https://biolegacyresearch.com/supreme-court-says-no-to-hearing-biogens-attempt-to-reinstate-tecfidera-patent/ 2022-10-05T04:01:00+00:00 https://biolegacyresearch.com/twice-weekly-glepaglutide-scores-in-phase-3-for-short-bowel-syndrome/ 2022-10-05T04:01:00+00:00 https://biolegacyresearch.com/u-s-has-spare-capacity-for-generic-drug-production-survey-finds/ 2022-10-05T04:01:00+00:00 https://biolegacyresearch.com/days-after-bsufa-iii-reauthorization-fda-launches-biosimilar-regulatory-pilot-program/ 2022-10-05T04:01:00+00:00 https://biolegacyresearch.com/fda-launches-star-pilot-program-for-quicker-review-of-efficacy-supplements/ 2022-10-05T21:20:52+00:00 https://biolegacyresearch.com/fda-publishes-a-slew-of-gdufa-iii-focused-guidances/ 2022-10-05T21:22:26+00:00 https://biolegacyresearch.com/fda-kicks-off-pilot-to-help-develop-novel-endpoints-for-rare-disease-trials/ 2022-10-05T21:22:30+00:00 https://biolegacyresearch.com/gold-nanoparticles-show-survival-benefit-in-als-trial/ 2022-10-05T21:22:38+00:00 https://biolegacyresearch.com/proposed-legislation-would-lift-cms-payment-rule-for-antiamyloid-antibodies/ 2022-10-06T21:30:45+00:00 https://biolegacyresearch.com/fda-publishes-more-gdufa-iii-focused-guidances-and-instructions/ 2022-10-06T21:32:00+00:00 https://biolegacyresearch.com/fda-publishes-guidance-on-post-crl-clarification-meetings/ 2022-10-06T21:32:00+00:00 https://biolegacyresearch.com/industry-efforts-to-expand-insulin-access-lacking-in-poorer-countries-group-says/ 2022-10-06T21:32:41+00:00 https://biolegacyresearch.com/fda-sets-user-fee-rates-for-fiscal-2023/ 2022-10-06T23:32:00+00:00 https://biolegacyresearch.com/fda-covis-debate-fate-of-preterm-birth-drug/ 2022-10-07T21:31:11+00:00 https://biolegacyresearch.com/despite-invalidated-blinding-taurx-touts-phase-3-win-for-alzheimers-drug/ 2022-10-07T21:44:07+00:00 https://biolegacyresearch.com/alkems-fenton-mo-plant-slapped-with-483-for-equipment-process-control-issues/ 2022-10-10T04:01:00+00:00 https://biolegacyresearch.com/republicans-introduce-bill-rolling-back-drug-pricing-reforms/ 2022-10-10T21:23:14+00:00 https://biolegacyresearch.com/mercks-potential-blockbuster-hypertension-drug-meets-endpoints-in-phase-3-study/ 2022-10-10T21:28:46+00:00 https://biolegacyresearch.com/european-commission-believes-teva-violated-antitrust-law-over-copaxone/ 2022-10-10T21:49:15+00:00 https://biolegacyresearch.com/ema-adopts-ich-guideline-on-testing-for-drug-carcinogenicity/ 2022-10-11T04:01:00+00:00 https://biolegacyresearch.com/baxter-healthcare-gets-form-483-for-lax-change-controls/ 2022-10-11T21:44:00+00:00 https://biolegacyresearch.com/eu-releases-first-document-on-new-framework-for-data-quality-and-integration/ 2022-10-11T21:44:00+00:00 https://biolegacyresearch.com/incentives-needed-to-promote-diversity-in-clinical-trials-experts-advise/ 2022-10-11T21:44:06+00:00 https://biolegacyresearch.com/albireo-pharma-reports-positive-results-in-pediatric-liver-disease-study/ 2022-10-11T21:44:30+00:00 https://biolegacyresearch.com/astrazeneca-teams-with-illumina-for-omics-research/ 2022-10-13T04:01:00+00:00 https://biolegacyresearch.com/fda-settles-lawsuit-with-drug-compounding-group/ 2022-10-13T04:01:00+00:00 https://biolegacyresearch.com/nimbus-joins-eli-lilly-in-investigational-metabolic-therapeutics/ 2022-10-13T04:01:00+00:00 https://biolegacyresearch.com/covid-19-exposed-supply-chain-challenges-new-procedures-needed-expert-says/ 2022-10-13T04:01:00+00:00 https://biolegacyresearch.com/most-safety-inspired-labeling-changes-arent-supported-by-published-studies-study-finds/ 2022-10-14T04:01:00+00:00 https://biolegacyresearch.com/fate-of-fda-orphan-drug-exclusivity-still-in-the-balance-agency-official-says/ 2022-10-14T04:01:00+00:00 https://biolegacyresearch.com/gsks-rsv-vaccine-highly-effective-against-severe-disease-in-older-adults-data-show/ 2022-10-14T04:01:00+00:00 https://biolegacyresearch.com/fda-offers-advice-on-cmc-postapproval-changes/ 2022-10-14T04:01:00+00:00 https://biolegacyresearch.com/fda-warning-letter-leads-eksa-mills-to-stop-production-at-mexico-plant/ 2022-10-14T04:01:00+00:00 https://biolegacyresearch.com/fresenius-kabis-illinois-plant-draws-form-483-for-batch-discrepancies-contamination/ 2022-10-14T22:42:36+00:00 https://biolegacyresearch.com/doj-pursues-alleged-trial-data-falsification-at-miami-site/ 2022-10-17T04:01:00+00:00 https://biolegacyresearch.com/hhs-cms-to-develop-plan-for-lowering-prescription-drug-costs-through-medicare/ 2022-10-17T04:01:00+00:00 https://biolegacyresearch.com/fda-offers-revised-guidance-on-prior-approval-supplements-under-gdufa-iii/ 2022-10-17T04:01:00+00:00 https://biolegacyresearch.com/covis-fda-go-head-to-head-over-makena-marketing-withdrawal/ 2022-10-17T22:10:00+00:00 https://biolegacyresearch.com/fda-issues-trio-of-oncology-drug-development-guidances/ 2022-10-17T22:12:35+00:00 https://biolegacyresearch.com/topline-data-support-self-administered-nasal-spray-for-heart-arrythmia/ 2022-10-17T22:15:11+00:00 https://biolegacyresearch.com/chmp-signs-off-on-10-new-drugs-during-october-meeting/ 2022-10-17T22:15:56+00:00 https://biolegacyresearch.com/icer-ublituximab-isnt-cost-effective-if-priced-like-ocrevus/ 2022-10-18T22:09:18+00:00 https://biolegacyresearch.com/fda-pushes-back-action-date-for-travere-therapeutics-nda-pending-rems-update/ 2022-10-18T22:09:44+00:00 https://biolegacyresearch.com/lilly-to-acquire-genetic-medicine-company-akouos-for-487-million/ 2022-10-18T22:10:07+00:00 https://biolegacyresearch.com/fda-adds-remote-tools-quality-and-risk-management-principles-to-inspection-programs/ 2022-10-18T22:10:33+00:00 https://biolegacyresearch.com/fda-advisory-panel-votes-to-withdraw-makena-from-market/ 2022-10-19T21:57:00+00:00 https://biolegacyresearch.com/califf-says-fdas-accelerated-approval-pathway-needs-makeover/ 2022-10-19T22:07:39+00:00 https://biolegacyresearch.com/fda-rolls-out-new-program-to-promote-use-of-real-world-evidence/ 2022-10-19T22:09:00+00:00 https://biolegacyresearch.com/inadequate-testing-validation-procedures-result-in-form-483-for-ohio-manufacturer/ 2022-10-19T22:11:24+00:00 https://biolegacyresearch.com/drug-studies-dont-include-enough-elderly-patients-say-fda-officials/ 2022-10-20T21:27:00+00:00 https://biolegacyresearch.com/takeda-sues-apotex-lilly-sues-dr-reddys-over-planned-generics/ 2022-10-20T21:27:40+00:00 https://biolegacyresearch.com/kite-grabs-refuge-license-for-new-car-t-platform/ 2022-10-20T21:28:14+00:00 https://biolegacyresearch.com/takeda-zedira-and-dr-falk-pharma-ink-deal-over-celiac-disease-candidate/ 2022-10-20T22:02:21+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-on-developing-gene-therapies-for-neurodegenerative-diseases/ 2022-10-21T23:30:48+00:00 https://biolegacyresearch.com/fda-suspends-memorandum-of-understanding-with-states-for-compounding-pharmacies/ 2022-10-21T23:31:17+00:00 https://biolegacyresearch.com/regeneron-gets-six-months-pediatric-exclusivity-for-eylea/ 2022-10-21T23:31:44+00:00 https://biolegacyresearch.com/fda-releases-four-guidances-on-topical-generics/ 2022-10-21T23:32:13+00:00 https://biolegacyresearch.com/hrsa-threatens-merck-with-fines-for-limiting-participation-in-340b-program/ 2022-10-24T21:32:53+00:00 https://biolegacyresearch.com/bayers-trial-supply-donation-program-wins-first-wcg-innovation-challenge/ 2022-10-24T21:35:18+00:00 https://biolegacyresearch.com/make-trial-participation-a-condition-of-coverage-for-certain-new-drugs-say-experts/ 2022-10-24T21:51:43+00:00 https://biolegacyresearch.com/fda-raps-another-catalent-facility-for-multiple-lapses/ 2022-10-25T04:01:00+00:00 https://biolegacyresearch.com/researchers-press-who-to-reconsider-costly-drugs-for-essential-medicines-list/ 2022-10-25T21:19:23+00:00 https://biolegacyresearch.com/fasenra-misses-in-phase-3-for-eosinophilic-esophagitis/ 2022-10-25T21:57:24+00:00 https://biolegacyresearch.com/nephron-sc-warning-letter-cites-multiple-cross-contamination-issues/ 2022-10-25T22:53:16+00:00 https://biolegacyresearch.com/fda-pushes-back-adcomm-meetings-including-one-to-discuss-first-otc-birth-control-pill-in-u-s/ 2022-10-26T22:19:59+00:00 https://biolegacyresearch.com/fda-lists-gdufa-research-priorities-for-fy-2023/ 2022-10-26T22:20:26+00:00 https://biolegacyresearch.com/acadia-sues-three-manufacturers-over-nuplazid-patent-infringement/ 2022-10-26T22:21:04+00:00 https://biolegacyresearch.com/jubilant-pharma-draws-form-483-for-inadequate-batch-failure-investigations/ 2022-10-26T22:21:40+00:00 https://biolegacyresearch.com/fda-issues-draft-guidance-on-developing-drugs-for-c-diff-infections/ 2022-10-27T22:57:18+00:00 https://biolegacyresearch.com/remove-politics-industry-influence-from-fda-decision-making-advocacy-group-advises/ 2022-10-27T22:57:48+00:00 https://biolegacyresearch.com/gsk-gets-a-partial-thumbs-up-for-anemia-drug-ends-plans-for-ra-drug/ 2022-10-27T22:58:18+00:00 https://biolegacyresearch.com/fda-rejects-gileads-hepatitis-d-therapy-hepcludex/ 2022-10-31T04:01:00+00:00 https://biolegacyresearch.com/ema-recommends-minimizing-jak-inhibitor-use-for-some-patients/ 2022-10-31T04:01:00+00:00 https://biolegacyresearch.com/fda-denies-petition-seeking-withdrawal-of-jazzs-lung-cancer-drug-approval/ 2022-10-31T04:01:00+00:00 https://biolegacyresearch.com/fda-panel-gives-unanimous-no-to-y-mabs-biologic-for-pediatric-neuroblastoma/ 2022-10-31T04:01:00+00:00 https://biolegacyresearch.com/fda-once-more-delays-action-on-pompe-disease-candidate/ 2022-11-01T04:01:00+00:00 https://biolegacyresearch.com/fda-releases-draft-guidance-on-assessing-growth-puberty-in-pediatric-trials/ 2022-11-01T04:01:00+00:00 https://biolegacyresearch.com/alnylam-scraps-trial-for-rare-eye-disease-blames-inflation-reduction-act/ 2022-11-01T04:01:00+00:00 https://biolegacyresearch.com/fda-publishes-final-guidance-for-small-entities-manufacturing-hct-ps/ 2022-11-01T04:01:00+00:00 https://biolegacyresearch.com/novartis-sues-generic-companies-to-protect-entresto-patent/ 2022-11-02T04:01:00+00:00 https://biolegacyresearch.com/pfizer-data-for-rsv-vaccine-candidate-in-pregnant-women-mostly-positive/ 2022-11-02T04:01:00+00:00 https://biolegacyresearch.com/fda-issues-draft-guidance-on-the-otc-monograph-user-fee-program/ 2022-11-02T04:01:00+00:00 https://biolegacyresearch.com/fda-updates-expanded-access-guidance-with-cures-act-and-fdara-requirements/ 2022-11-02T04:01:00+00:00 https://biolegacyresearch.com/use-of-expedited-approval-pathways-continues-upward-trend-fda-study-shows/ 2022-11-02T04:01:00+00:00 https://biolegacyresearch.com/fda-advisors-vote-in-favor-of-cders-quality-management-maturity-program/ 2022-11-02T21:33:00+00:00 https://biolegacyresearch.com/two-big-ticket-hemophilia-gene-therapies-would-be-worth-the-cost-icer-says/ 2022-11-02T21:34:42+00:00 https://biolegacyresearch.com/arcturus-inks-multimillion-dollar-deal-with-csl-to-develop-mrna-vaccines/ 2022-11-02T21:36:09+00:00 https://biolegacyresearch.com/fda-warns-lupin-for-lack-of-plan-to-correct-cleaning-and-contamination-issues/ 2022-11-02T21:37:00+00:00 https://biolegacyresearch.com/fda-redefines-face-to-face-meetings-to-include-virtual-option/ 2022-11-04T04:01:00+00:00 https://biolegacyresearch.com/adcomm-approves-of-fda-plans-to-further-develop-and-expand-kasa-program/ 2022-11-04T04:01:00+00:00 https://biolegacyresearch.com/fda-cites-sovereign-pharmaceuticals-for-multiple-quality-control-problems/ 2022-11-04T04:01:00+00:00 https://biolegacyresearch.com/abbvie-sues-generics-makers-for-alleged-infringement-of-orilissa-patents/ 2022-11-04T04:01:00+00:00 https://biolegacyresearch.com/fda-finalizes-guidance-on-cross-labeling-of-combination-oncology-drugs/ 2022-11-04T04:01:00+00:00 https://biolegacyresearch.com/cdc-updates-opioid-prescribing-recommendations-says-previous-guidelines-misapplied/ 2022-11-04T21:38:43+00:00 https://biolegacyresearch.com/new-data-delay-fda-action-on-apellis-pharmaceuticals-pegcetacoplan-for-rare-eye-disease/ 2022-11-04T21:39:02+00:00 https://biolegacyresearch.com/fda-adopts-ich-final-guidance-on-bioanalytical-method-validation/ 2022-11-04T21:39:17+00:00 https://biolegacyresearch.com/ema-guidance-sets-out-criteria-process-for-requesting-orphan-drug-designation/ 2022-11-07T22:12:00+00:00 https://biolegacyresearch.com/supreme-court-to-take-up-amgen-patent-case-over-cholesterol-drug/ 2022-11-07T22:23:53+00:00 https://biolegacyresearch.com/gsks-blenrep-misses-required-confirmatory-trial/ 2022-11-07T22:39:44+00:00 https://biolegacyresearch.com/academics-advocacy-groups-say-pasteur-act-wont-stem-antibiotic-resistant-infections/ 2022-11-08T05:05:00+00:00 https://biolegacyresearch.com/neurotechs-treatment-for-macular-telangiectasia-sees-positive-phase-3-results/ 2022-11-08T22:18:00+00:00 https://biolegacyresearch.com/andas-must-demonstrate-sameness-of-active-ingredients-fda-draft-guidance-says/ 2022-11-08T22:49:28+00:00 https://biolegacyresearch.com/pharma-reacts-with-concern-to-fdas-new-premarket-safety-analytics-efforts/ 2022-11-08T23:06:00+00:00 https://biolegacyresearch.com/adcomm-votes-asthma-combo-up-for-adults-down-for-children/ 2022-11-08T23:28:43+00:00 https://biolegacyresearch.com/fda-advisory-panel-votes-against-verus-covid-19-drug-candidate/ 2022-11-09T22:25:00+00:00 https://biolegacyresearch.com/adc-drops-goal-of-accelerated-approval-for-cami-in-hodgkins/ 2022-11-09T22:26:14+00:00 https://biolegacyresearch.com/fda-recommends-umbrella-trials-for-studying-multiple-versions-of-cell-gene-therapies/ 2022-11-09T22:28:00+00:00 https://biolegacyresearch.com/fda-slaps-abraxis-plant-with-warning-letter-for-contamination-issues/ 2022-11-09T22:28:25+00:00 https://biolegacyresearch.com/fda-publishes-mapp-on-quality-assessment-for-products-in-expedited-programs/ 2022-11-10T22:32:00+00:00 https://biolegacyresearch.com/fda-hands-brainstorm-refusal-to-file-letter-for-als-treatment/ 2022-11-10T22:32:55+00:00 https://biolegacyresearch.com/eqrx-drops-us-plans-for-sugemalimab-as-nsclc-therapy/ 2022-11-10T22:33:00+00:00 https://biolegacyresearch.com/fda-seeks-comment-on-ich-draft-guidance-on-viral-safety-of-biotechnology-products/ 2022-11-10T22:54:17+00:00 https://biolegacyresearch.com/gsk-to-restrict-ovarian-cancer-drugs-indication/ 2022-11-11T22:15:00+00:00 https://biolegacyresearch.com/ftc-challenges-abuse-of-fdas-orange-book-to-block-drug-competition/ 2022-11-11T22:15:00+00:00 https://biolegacyresearch.com/fda-pushes-back-comment-period-on-irb-informed-consent-rules-until-end-of-year/ 2022-11-11T22:15:38+00:00 https://biolegacyresearch.com/appco-pharma-gets-form-483-for-missing-records/ 2022-11-11T22:15:46+00:00 https://biolegacyresearch.com/in-another-alzheimers-flop-gantenerumab-fails-twin-phase-3-trials/ 2022-11-14T22:35:56+00:00 https://biolegacyresearch.com/oregon-ag-sues-four-pharma-companies-for-blocking-androgel-competitors/ 2022-11-14T22:36:21+00:00 https://biolegacyresearch.com/indivior-to-acquire-overdose-reversal-drugmaker-opiant-pharmaceuticals/ 2022-11-14T22:36:46+00:00 https://biolegacyresearch.com/imprimisrx-gets-form-483-for-unsanitary-conditions-drug-quality-issues/ 2022-11-14T22:37:12+00:00 https://biolegacyresearch.com/doj-rejects-floridas-claim-fda-is-stalling-on-drug-imports-from-canada/ 2022-11-15T22:25:00+00:00 https://biolegacyresearch.com/immunogen-wins-accelerated-approval-for-ovarian-cancer-drug-elahere/ 2022-11-15T22:26:00+00:00 https://biolegacyresearch.com/phrma-jj-join-pfizers-fight-to-keep-patient-reimbursement-program-alive/ 2022-11-15T22:26:17+00:00 https://biolegacyresearch.com/fda-seeks-comments-on-approving-naloxone-for-nonprescription-use/ 2022-11-15T22:49:00+00:00 https://biolegacyresearch.com/abbvie-and-jj-win-federal-patent-case-thwarting-generic-of-blockbuster-imbruvica/ 2022-11-17T05:01:00+00:00 https://biolegacyresearch.com/fda-expert-panel-recommends-ardelyxs-ckd-drug-despite-misgivings/ 2022-11-17T05:01:00+00:00 https://biolegacyresearch.com/aarkish-pharmaceuticals-hit-with-form-483-for-lax-records/ 2022-11-17T05:01:00+00:00 https://biolegacyresearch.com/sellas-amends-leukemia-trial-as-patients-live-twice-as-long-as-expected/ 2022-11-17T05:01:00+00:00 https://biolegacyresearch.com/fdas-onsite-drug-inspections-ramped-up-in-fiscal-2022-says-ora-official/ 2022-11-18T05:01:00+00:00 https://biolegacyresearch.com/industry-coalition-pushes-congress-to-tackle-threat-of-antimicrobial-resistance/ 2022-11-18T05:01:00+00:00 https://biolegacyresearch.com/fda-approves-rezvoglar-as-second-interchangeable-biosimilar-insulin/ 2022-11-18T05:01:00+00:00 https://biolegacyresearch.com/fda-issues-another-483-to-lupin-facility-over-manufacturing-deficiencies/ 2022-11-18T05:01:00+00:00 https://biolegacyresearch.com/pazdur-califf-agree-accelerated-approval-pathway-badly-in-need-of-reform/ 2022-11-18T22:50:54+00:00 https://biolegacyresearch.com/who-pandemic-pact-wants-manufacturers-to-disclose-prices-deals/ 2022-11-18T22:51:24+00:00 https://biolegacyresearch.com/regeneron-teams-with-cytomx-for-bispecific-cancer-drug-development/ 2022-11-21T05:01:00+00:00 https://biolegacyresearch.com/fda-investigators-relentless-in-pursuit-of-data-integrity-issues-experts-say/ 2022-11-21T05:01:00+00:00 https://biolegacyresearch.com/merck-expands-its-hematology-reach-with-1-35b-purchase-of-imago-biosciences/ 2022-11-21T22:16:44+00:00 https://biolegacyresearch.com/gene-therapy-slows-decline-in-genetic-fatal-childhood-dementia/ 2022-11-21T22:21:02+00:00 https://biolegacyresearch.com/ptab-upholds-pfizers-patent-claims-on-gene-therapy-for-hemophilia-b/ 2022-11-21T22:50:15+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-to-address-beta-lactam-products-shortage/ 2022-11-22T05:01:00+00:00 https://biolegacyresearch.com/complete-archives-with-clear-file-names-key-to-successful-fda-inspection/ 2022-11-22T21:52:00+00:00 https://biolegacyresearch.com/two-years-after-winning-accelerated-approval-gsk-pulls-blenrep-at-fdas-request/ 2022-11-22T21:55:56+00:00 https://biolegacyresearch.com/bipartisan-bill-would-allow-research-on-schedule-i-breakthrough-therapy-drugs/ 2022-11-22T22:21:30+00:00 https://biolegacyresearch.com/fda-proposes-to-add-two-apis-to-503b-bulks-list-says-no-to-three-others/ 2022-11-22T22:54:49+00:00 https://biolegacyresearch.com/alleging-monopoly-pension-funds-sue-bms-and-generics-firms-over-pay-to-play-deals/ 2022-11-23T21:44:38+00:00 https://biolegacyresearch.com/hemophilia-gene-therapy-wins-fda-nod-and-title-of-priciest-drug-ever/ 2022-11-23T22:12:00+00:00 https://biolegacyresearch.com/a-critical-eye-on-accelerated-approval/ 2022-11-23T22:39:00+00:00 https://biolegacyresearch.com/biologics-firm-draws-fda-warning-letter-for-unapproved-cellular-products/ 2022-11-28T05:01:00+00:00 https://biolegacyresearch.com/accelerated-approval-changes-likely-in-2023/ 2022-11-28T22:01:00+00:00 https://biolegacyresearch.com/axsome-therapeutics-dextromethorphan-bupropion-blend-reduces-agitation-in-alzheimers/ 2022-11-28T22:09:14+00:00 https://biolegacyresearch.com/following-crl-spectrum-drops-nsclc-drug-candidate/ 2022-11-28T22:12:37+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-on-use-of-fecal-microbiota-for-transplantation/ 2022-11-28T22:37:54+00:00 https://biolegacyresearch.com/inspection-readiness-tips-for-handling-original-documents-and-tracking-transfers/ 2022-11-29T21:19:00+00:00 https://biolegacyresearch.com/fda-warns-amgens-osteoporosis-drug-could-cause-severe-hypocalcemia-in-patients-with-advanced-kidney-disease/ 2022-11-29T22:25:41+00:00 https://biolegacyresearch.com/skinny-labeling-saved-medicare-1-5-billion-over-5-years-study-finds/ 2022-11-29T22:28:22+00:00 https://biolegacyresearch.com/genentech-pulls-tecentriq-indication-in-bladder-cancer-two-plus-years-after-trial-failure/ 2022-11-29T22:31:00+00:00 https://biolegacyresearch.com/trial-site-draws-fda-warning-letter-over-combination-product/ 2022-11-30T21:53:34+00:00 https://biolegacyresearch.com/aa-clean-up-continues-with-fda-pulling-approval-for-viatris-antibiotic-cream/ 2022-11-30T21:56:31+00:00 https://biolegacyresearch.com/eisais-lecanemab-hits-all-the-high-points-in-alzheimers-study/ 2022-11-30T22:16:43+00:00 https://biolegacyresearch.com/fda-approves-first-fecal-microbiota-treatment/ 2022-11-30T22:54:31+00:00 https://biolegacyresearch.com/taurx-keeps-the-faith-on-its-anti-tau-agent/ 2022-12-02T05:01:00+00:00 https://biolegacyresearch.com/argenx-picks-up-priority-review-voucher-for-102-million/ 2022-12-02T05:01:00+00:00 https://biolegacyresearch.com/in-wake-of-gantenerumabs-failure-roche-scraps-all-studies/ 2022-12-02T05:01:00+00:00 https://biolegacyresearch.com/sanofis-drug-candidate-targeting-sleeping-sickness-shows-high-efficacy/ 2022-12-02T05:01:00+00:00 https://biolegacyresearch.com/ema-safety-committee-recommends-pulling-cough-meds-from-eu-market/ 2022-12-02T21:58:00+00:00 https://biolegacyresearch.com/ongoing-drug-shortages-more-challenging-for-fda-than-new-ones/ 2022-12-02T21:58:16+00:00 https://biolegacyresearch.com/jj-alleges-amgens-proposed-biosimilar-infringes-on-stelara-patents/ 2022-12-02T21:58:56+00:00 https://biolegacyresearch.com/fda-offers-guidance-on-bioequivalence-studies-presubmission-correspondence/ 2022-12-02T21:59:00+00:00 https://biolegacyresearch.com/new-law-creates-registration-process-for-marijuana-based-drug-development/ 2022-12-05T22:11:00+00:00 https://biolegacyresearch.com/califfs-vision-an-fda-as-automated-as-amazon/ 2022-12-05T22:11:00+00:00 https://biolegacyresearch.com/fda-adopts-ich-e19-guideline-on-selective-safety-data-collection/ 2022-12-05T22:14:00+00:00 https://biolegacyresearch.com/novartis-pluvicto-racks-up-second-win-for-psma-prostate-cancer/ 2022-12-05T22:16:00+00:00 https://biolegacyresearch.com/ich-signals-all-systems-go-for-continuous-manufacturing/ 2022-12-06T22:14:00+00:00 https://biolegacyresearch.com/summit-gets-licensing-rights-for-bispecific-antibody-targeting-nsclc/ 2022-12-06T22:14:50+00:00 https://biolegacyresearch.com/sponsors-can-seek-alternative-dosing-regimens-for-pd-blocking-antibodies/ 2022-12-06T22:15:26+00:00 https://biolegacyresearch.com/inspection-readiness-ensuring-access-to-contracted-archives-and-documenting-drafts/ 2022-12-06T22:15:58+00:00 https://biolegacyresearch.com/federal-ruling-may-allow-pharma-giants-to-escape-thousands-of-zantac-lawsuits/ 2022-12-07T23:07:24+00:00 https://biolegacyresearch.com/seven-unsupported-drug-price-hikes-cost-consumers-805-million-in-2021-says-icer/ 2022-12-07T23:07:55+00:00 https://biolegacyresearch.com/actelion-faces-rico-suit-for-allegedly-overcharging-for-blood-pressure-drugs/ 2022-12-07T23:08:30+00:00 https://biolegacyresearch.com/fda-inspection-readiness-be-able-to-produce-your-documents-quickly/ 2022-12-07T23:09:05+00:00 https://biolegacyresearch.com/fda-proposes-more-detailed-annual-reporting-for-inds/ 2022-12-09T05:01:00+00:00 https://biolegacyresearch.com/fda-places-sun-pharmaceutical-on-import-alert-over-cgmp-problems/ 2022-12-09T05:01:00+00:00 https://biolegacyresearch.com/untitled-letter-warns-valisure-about-pharmacy-related-lapses/ 2022-12-09T05:01:00+00:00 https://biolegacyresearch.com/fda-targets-specific-homeopathic-drug-categories-in-final-guidance/ 2022-12-09T05:01:00+00:00 https://biolegacyresearch.com/califf-projects-cell-gene-therapies-will-drive-growth-over-next-five-years/ 2022-12-12T05:01:11+00:00 https://biolegacyresearch.com/federal-judge-dismisses-many-cases-alleging-harm-from-mercks-shingles-vaccine/ 2022-12-12T05:01:13+00:00 https://biolegacyresearch.com/generics-and-api-manufacturers-aurobindo-and-lupin-slapped-with-lengthy-483s/ 2022-12-12T05:01:14+00:00 https://biolegacyresearch.com/guidance-clarifies-how-to-handle-aluminum-levels-in-parenteral-nutrition-products/ 2022-12-12T05:01:16+00:00 https://biolegacyresearch.com/amgen-to-gain-eye-disease-blockbuster-drug-in-28b-horizon-therapeutics-buyout/ 2022-12-12T22:52:20+00:00 https://biolegacyresearch.com/two-menin-inhibitors-score-in-early-leukemia-studies/ 2022-12-12T22:52:24+00:00 https://biolegacyresearch.com/consolidated-chemical-sees-483-for-lack-of-water-testing-poor-building-condition/ 2022-12-12T22:52:30+00:00 https://biolegacyresearch.com/take-fda-untitled-letters-seriously-advises-former-agency-compliance-director/ 2022-12-12T22:52:40+00:00 https://biolegacyresearch.com/combination-mrna-keytruda-product-shows-efficacy-in-melanoma/ 2022-12-14T05:01:00+00:00 https://biolegacyresearch.com/takeda-to-aquire-nimbus-and-its-promising-tyk2-inhibitor-in-6b-deal/ 2022-12-14T05:01:02+00:00 https://biolegacyresearch.com/the-year-in-insulin-pricing-price-drops-achieved-for-seniors-but-no-one-else/ 2022-12-14T05:01:55+00:00 https://biolegacyresearch.com/fda-advisory-panel-votes-down-cytokinetics-heart-failure-candidate/ 2022-12-14T05:01:57+00:00 https://biolegacyresearch.com/the-year-in-insulin-pricing-states-seeking-solutions/ 2022-12-14T22:31:16+00:00 https://biolegacyresearch.com/biden-administration-proposes-change-to-generic-drug-coverage-under-aca/ 2022-12-14T22:31:42+00:00 https://biolegacyresearch.com/fda-issues-updated-guidance-on-developing-pulmonary-tuberculosis-drugs/ 2022-12-14T22:31:45+00:00 https://biolegacyresearch.com/centrient-pharmaceuticals-receives-warning-letter-for-indian-plant/ 2022-12-14T22:31:48+00:00 https://biolegacyresearch.com/adcomm-recommends-combining-primary-and-booster-covid-strains-in-one-annual-shot/ 2023-01-27T05:01:00+00:00 https://biolegacyresearch.com/sen-warren-presses-ftc-to-scrutinize-two-pending-pharma-mergers/ 2023-01-30T05:01:00+00:00 https://biolegacyresearch.com/senators-re-introduce-bill-to-create-uspto-fda-task-force/ 2023-01-30T05:01:00+00:00 https://biolegacyresearch.com/fda-pulls-evusheld-eua-but-astrazeneca-has-another-antibody-in-the-wings/ 2023-01-30T05:01:00+00:00 https://biolegacyresearch.com/dozens-of-pediatric-trials-failed-to-properly-report-results-study-finds/ 2023-01-30T05:01:00+00:00 https://biolegacyresearch.com/amgen-launches-long-approved-humira-biosimilar-amjevita/ 2023-01-31T05:01:00+00:00 https://biolegacyresearch.com/fda-issues-draft-guidance-on-externally-controlled-trials/ 2023-01-31T05:01:00+00:00 https://biolegacyresearch.com/lgm-pharma-enters-consent-decree-following-allegations-of-adulterated-drugs/ 2023-01-31T05:01:00+00:00 https://biolegacyresearch.com/appeals-court-decides-in-favor-of-pharma-in-340b-battle/ 2023-01-31T05:01:00+00:00 https://biolegacyresearch.com/ich-finalizes-revised-quality-risk-management-guideline/ 2023-01-31T05:05:38+00:00 https://biolegacyresearch.com/icer-questions-benefit-of-astellas-pharmas-hot-flash-candidate/ 2023-02-01T05:01:00+00:00 https://biolegacyresearch.com/fda-seeks-comments-on-ich-draft-guideline-on-bioequivalence-testing-for-solid-oral-drugs/ 2023-02-01T05:01:00+00:00 https://biolegacyresearch.com/industry-nonprofit-issues-standards-for-data-sharing/ 2023-02-01T05:01:00+00:00 https://biolegacyresearch.com/cder-reports-show-covid-and-generic-drug-successes-in-2022/ 2023-02-02T05:01:00+00:00 https://biolegacyresearch.com/bayer-serono-will-limit-340b-drug-price-discounts/ 2023-02-02T05:01:00+00:00 https://biolegacyresearch.com/supply-chain-healthier-than-it-seems-but-generics-face-special-challenges/ 2023-02-02T05:01:00+00:00 https://biolegacyresearch.com/lyne-laboratories-gets-form-483-for-inadequate-complaint-investigations-batch-records/ 2023-02-02T05:01:00+00:00 https://biolegacyresearch.com/quality-experts-point-the-way-to-a-mature-quality-culture/ 2023-02-02T05:01:00+00:00 https://biolegacyresearch.com/fate-of-70-fda-guidances-hangs-in-the-balance-as-end-of-public-emergency-approaches/ 2023-02-06T05:01:00+00:00 https://biolegacyresearch.com/two-years-after-fda-rejection-mesoblast-resubmits-bla-for-remestemcel-l/ 2023-02-06T05:01:00+00:00 https://biolegacyresearch.com/what-washington-is-doing-to-improve-the-drug-supply-chain/ 2023-02-06T05:01:00+00:00 https://biolegacyresearch.com/sanofi-regeneron-push-supreme-court-to-deny-amgens-cholesterol-patent-monopoly/ 2023-02-07T05:01:00+00:00 https://biolegacyresearch.com/ema-seeks-comments-on-new-stakeholder-platform-for-improving-trials/ 2023-02-07T05:01:00+00:00 https://biolegacyresearch.com/sage-and-biogens-depression-drug-candidate-gets-priority-review/ 2023-02-07T05:01:00+00:00 https://biolegacyresearch.com/fdas-fiscal-2021-postmarket-report-shows-sponsor-compliance-lagging/ 2023-02-07T05:01:00+00:00 https://biolegacyresearch.com/phrma-faces-setback-in-litigation-over-canadian-drug-importation/ 2023-02-08T05:01:00+00:00 https://biolegacyresearch.com/drugmakers-fail-to-convince-court-to-kill-terror-funding-lawsuit/ 2023-02-08T05:01:00+00:00 https://biolegacyresearch.com/ema-pilots-refinable-pediatric-drug-studies-program/ 2023-02-08T05:01:00+00:00 https://biolegacyresearch.com/president-biden-continues-pushing-for-insulin-price-caps-in-sotu-address/ 2023-02-08T05:01:00+00:00 https://biolegacyresearch.com/federal-judge-says-plaintiffs-in-zantac-case-have-to-file-individual-complaints/ 2023-02-09T05:00:00+00:00 https://biolegacyresearch.com/fda-raps-italian-drug-facility-for-microbiological-contamination/ 2023-02-09T05:00:00+00:00 https://biolegacyresearch.com/ema-clarifies-its-policy-on-biosimilar-interchangeability/ 2023-02-09T05:00:00+00:00 https://biolegacyresearch.com/drugmakers-seek-clarification-of-draft-guidance-on-bioequivalence/ 2023-02-09T05:00:00+00:00 https://biolegacyresearch.com/califf-fields-supply-chain-questions-from-house-lawmakers-in-covid-hearing/ 2023-02-09T05:01:00+00:00 https://biolegacyresearch.com/galapagos-misses-endpoints-in-crohns-disease-trial-will-not-seek-eu-approval/ 2023-02-09T05:01:00+00:00 https://biolegacyresearch.com/eigers-peginterferon-lambda-cuts-covid-19-hospitalizations-in-half-trial-shows/ 2023-02-09T05:01:00+00:00 https://biolegacyresearch.com/in-8-to-5-vote-fda-adcomm-greenlights-gsk-rectal-cancer-trial/ 2023-02-09T05:01:00+00:00 https://biolegacyresearch.com/fda-expands-ibuprofen-compounding-guidance-to-state-and-federal-pharmacies/ 2023-02-09T05:01:00+00:00 https://biolegacyresearch.com/fda-calls-for-long-term-safety-studies-in-neonatal-product-development/ 2023-02-10T05:01:00+00:00 https://biolegacyresearch.com/phathom-receives-two-crls-over-nitrosamine-impurities/ 2023-02-10T05:01:00+00:00 https://biolegacyresearch.com/adcomm-process-is-messy-but-necessary-and-needs-reform-califf-says/ 2023-02-10T05:01:00+00:00 https://biolegacyresearch.com/cms-guidance-requires-drugmakers-to-pay-up-if-price-hikes-exceed-inflation-rate/ 2023-02-13T05:01:00+00:00 https://biolegacyresearch.com/bipartisan-bills-to-limit-drug-prices-clear-senate-judiciary-committee/ 2023-02-13T05:01:00+00:00 https://biolegacyresearch.com/sun-pharmaceuticals-recalls-blood-pressure-drug-for-impurity/ 2023-02-13T05:01:00+00:00 https://biolegacyresearch.com/form-483-finds-multiple-sterilization-issues-in-pharmacy-plus-inspection/ 2023-02-13T05:01:00+00:00 https://biolegacyresearch.com/ema-to-review-pseudoephedrine-drugs-after-reports-of-brain-vasoconstriction/ 2023-02-13T05:01:00+00:00 https://biolegacyresearch.com/fda-on-track-with-pdufa-vii-goals-centered-on-dht-related-submissions/ 2023-02-14T05:01:00+00:00 https://biolegacyresearch.com/cell-and-gene-therapy-project-orbis-still-just-a-concept-says-fda/ 2023-02-14T05:01:00+00:00 https://biolegacyresearch.com/one-in-10-drugs-approved-by-fda-did-not-achieve-all-trial-endpoints-researchers-say/ 2023-02-14T05:01:00+00:00 https://biolegacyresearch.com/biocon-and-viatris-draw-complete-response-letter-for-bevacizumab-bla/ 2023-02-14T05:01:00+00:00 https://biolegacyresearch.com/joint-adcomm-signals-unanimous-support-for-otc-naloxone-nasal-spray/ 2023-02-15T05:01:00+00:00 https://biolegacyresearch.com/hhs-pilots-will-explore-ways-to-lower-drug-prices/ 2023-02-15T05:01:00+00:00 https://biolegacyresearch.com/opq-conducts-more-remote-preapproval-inspections-in-2022/ 2023-02-16T05:01:00+00:00 https://biolegacyresearch.com/one-fifth-of-drugs-approved-in-u-s-were-rejected-elsewhere-study-shows/ 2023-02-16T05:01:00+00:00 https://biolegacyresearch.com/failure-to-stop-ira-may-cost-phrma-members-industry-watchers-speculate/ 2023-02-16T05:01:00+00:00 https://biolegacyresearch.com/for-nash-resmetirom-not-obeticholic-acid-may-be-cost-effective-icer-says/ 2023-02-16T05:01:00+00:00 https://biolegacyresearch.com/senate-committee-takes-up-bipartisan-bill-to-curb-pbm-pricing-practices/ 2023-02-16T05:01:00+00:00 https://biolegacyresearch.com/amicus-briefs-support-sanofi-and-regeneron-in-amgen-supreme-court-patent-case/ 2023-02-16T05:01:00+00:00 https://biolegacyresearch.com/pfizer-drops-half-of-enrollment-in-lyme-disease-trial-due-to-sites-gcp-infractions/ 2023-02-17T05:01:00+00:00 https://biolegacyresearch.com/know-your-rights-during-an-fda-inspection-expert-says/ 2023-02-21T05:01:00+00:00 https://biolegacyresearch.com/fda-spells-out-its-commitments-on-product-specific-guidance-meetings/ 2023-02-21T05:01:00+00:00 https://biolegacyresearch.com/fda-may-ask-congress-for-expanded-authority-over-opioids/ 2023-02-21T05:01:00+00:00 https://biolegacyresearch.com/fda-approves-first-treatment-for-geographic-atrophy-accepts-nda-for-same-indication/ 2023-02-21T05:01:00+00:00 https://biolegacyresearch.com/icer-to-be-cost-effective-briumvi-should-be-84-percent-cheaper/ 2023-02-21T05:01:00+00:00 https://biolegacyresearch.com/fda-grants-accelerated-approval-to-traveres-rare-kidney-disease-treatment/ 2023-02-21T05:01:00+00:00 https://biolegacyresearch.com/theravance-viatris-sue-to-block-copies-of-yupelri-copd-drug/ 2023-02-21T05:01:00+00:00 https://biolegacyresearch.com/ani-pharmaceuticals-rapped-for-complaint-handling-sops/ 2023-02-23T05:00:00+00:00 https://biolegacyresearch.com/senators-join-in-bipartisan-push-for-antiamyloid-antibody-coverage/ 2023-02-23T05:00:00+00:00 https://biolegacyresearch.com/hhs-lists-planned-fda-rules-likely-to-have-significant-economic-impacts/ 2023-02-23T05:00:00+00:00 https://biolegacyresearch.com/fda-sees-spike-in-drug-applications-that-involve-ai-tools/ 2023-02-23T05:00:00+00:00 https://biolegacyresearch.com/astrazeneca-expands-gastric-cancer-reach-with-kym-biosciences-adc-candidate/ 2023-02-23T05:01:00+00:00 https://biolegacyresearch.com/cms-signals-its-open-to-negotiation-on-antiamyloid-antibody-coverage/ 2023-02-23T05:01:00+00:00 https://biolegacyresearch.com/icosavax-gains-fast-track-for-innovative-vaccine/ 2023-02-23T05:01:00+00:00 https://biolegacyresearch.com/lawmakers-warn-patent-office-of-keytruda-patent-abuse/ 2023-02-23T05:01:00+00:00 https://biolegacyresearch.com/fda-offers-advice-on-neovascular-age-related-macular-degeneration-drug-trials/ 2023-02-27T05:01:00+00:00 https://biolegacyresearch.com/emas-chmp-recommends-approval-of-eight-new-medicines/ 2023-02-27T05:01:00+00:00 https://biolegacyresearch.com/fda-raps-api-facility-in-nebraska-for-microbial-contamination/ 2023-02-27T05:01:00+00:00 https://biolegacyresearch.com/researchers-urge-fda-to-quickly-withdraw-accelerated-approvals-after-negative-trial-data/ 2023-02-27T05:01:00+00:00 https://biolegacyresearch.com/gene-therapy-consortium-to-launch-pilot-for-rare-diseases-says-cbers-marks/ 2023-02-27T05:01:00+00:00 https://biolegacyresearch.com/biomarins-hemophilia-gene-therapy-improves-bleeding-rates-for-two-years/ 2023-02-27T05:01:00+00:00 https://biolegacyresearch.com/coalition-of-states-sues-fda-over-abortion-pill-rems/ 2023-02-27T05:01:00+00:00 https://biolegacyresearch.com/california-otc-drugmaker-rapped-for-lacking-written-procedures/ 2023-02-28T05:01:00+00:00 https://biolegacyresearch.com/fda-hiring-ethicists-to-help-agency-frame-difficult-issues-says-califf/ 2023-03-01T05:01:00+00:00 https://biolegacyresearch.com/jazz-pharmaceuticals-loses-narcolepsy-drug-patent-appeal/ 2023-03-01T05:01:00+00:00 https://biolegacyresearch.com/controversial-fda-official-behind-aduhelm-approval-departs-fda/ 2023-03-01T05:01:00+00:00 https://biolegacyresearch.com/advisory-committee-endorses-pfizers-rsv-vaccine-candidate/ 2023-03-01T05:01:00+00:00 https://biolegacyresearch.com/ogd-reports-uptick-in-generic-approvals-for-2022/ 2023-03-01T05:01:00+00:00 https://biolegacyresearch.com/eli-lillys-insulin-price-cuts-pressure-other-producers-to-follow-suit/ 2023-03-01T05:01:00+00:00 https://biolegacyresearch.com/adcomm-gives-green-light-to-gsks-rsv-vaccine/ 2023-03-01T05:01:00+00:00 https://biolegacyresearch.com/fda-nixes-cytokinetics-nda-for-heart-failure-drug/ 2023-03-02T05:01:00+00:00 https://biolegacyresearch.com/student-led-nonprofit-petitions-fda-to-strengthen-trial-reporting-enforcement/ 2023-03-02T05:01:00+00:00 https://biolegacyresearch.com/cder-prioritized-safety-of-covid-19-products-opioids-in-2022-report-says/ 2023-03-02T05:01:00+00:00 https://biolegacyresearch.com/senators-re-introduce-bill-to-close-rems-patent-loophole/ 2023-03-02T05:01:00+00:00 https://biolegacyresearch.com/eisai-defends-leqembi-pricing-in-face-of-icer-recommended-cuts/ 2023-03-03T05:01:00+00:00 https://biolegacyresearch.com/fda-offers-guidance-on-potency-assays-for-antibodies-that-target-viral-proteins/ 2023-03-03T05:01:00+00:00 https://biolegacyresearch.com/novo-nordisk-sanofi-unlikely-to-cut-insulin-prices-despite-pressure-from-senator/ 2023-03-03T05:01:00+00:00 https://biolegacyresearch.com/fda-denies-petition-by-cassava-investor-to-grant-simufilam-breakthrough-designation/ 2023-03-03T05:01:00+00:00 https://biolegacyresearch.com/catalyst-launches-patent-suit-against-lupin-over-firdapse-generic/ 2023-03-03T05:01:00+00:00 https://biolegacyresearch.com/as-dscsa-deadline-looms-manufacturers-supply-chains-still-have-far-to-go/ 2023-03-06T05:01:00+00:00 https://biolegacyresearch.com/fda-grants-leqembi-priority-review-for-full-approval/ 2023-03-06T05:01:00+00:00 https://biolegacyresearch.com/intercept-settles-ocaliva-lawsuits-with-apotex-msn-labs/ 2023-03-06T05:01:00+00:00 https://biolegacyresearch.com/cipla-plant-rapped-for-serious-quality-and-systems-lapses/ 2023-03-07T05:01:00+00:00 https://biolegacyresearch.com/b-braun-gets-form-483-for-batch-discrepancies-quality-lapses/ 2023-03-07T05:01:00+00:00 https://biolegacyresearch.com/fda-and-ftc-team-up-to-counter-misleading-info-about-biosimilars/ 2023-03-07T05:01:00+00:00 https://biolegacyresearch.com/genentech-seeks-patent-royalties-from-biogen-for-blockbuster-ms-drug/ 2023-03-07T05:01:00+00:00 https://biolegacyresearch.com/many-accelerated-approval-drug-labels-lack-required-marketing-information/ 2023-03-07T05:01:00+00:00 https://biolegacyresearch.com/cms-releases-list-of-27-drugs-to-be-hit-with-ira-related-fines-in-2025/ 2023-03-15T04:01:00+00:00 https://biolegacyresearch.com/fda-offers-advice-on-ndas-for-postoperative-local-anesthetics/ 2023-03-15T04:01:00+00:00 https://biolegacyresearch.com/fda-shares-latest-thinking-on-electronic-systems-signatures-and-records-in-trials/ 2023-03-15T04:01:00+00:00 https://biolegacyresearch.com/arkansas-drug-facility-hit-for-control-and-quality-lapses/ 2023-03-15T04:01:00+00:00 https://biolegacyresearch.com/paxlovid-gets-advisory-panel-support-for-full-fda-approval/ 2023-03-16T04:01:00+00:00 https://biolegacyresearch.com/fda-publishes-final-guidance-on-meaning-of-suspect-and-illegitimate-in-dscsa/ 2023-03-16T04:01:00+00:00 https://biolegacyresearch.com/texas-judge-will-rule-soon-on-mifepristone-case/ 2023-03-16T04:01:00+00:00 https://biolegacyresearch.com/fda-ema-scientific-advice-program-continued-in-the-pandemic-but-overall-uptake-is-low/ 2023-03-17T04:01:00+00:00 https://biolegacyresearch.com/sanofi-joins-other-insulin-titans-in-price-cuts-under-pressure-to-do-more/ 2023-03-17T04:01:00+00:00 https://biolegacyresearch.com/icer-aims-to-consider-health-equity-in-its-product-value-assessments/ 2023-03-17T04:01:00+00:00 https://biolegacyresearch.com/fda-offers-guidance-on-use-of-pharmacogenomic-data/ 2023-03-17T04:01:00+00:00 https://biolegacyresearch.com/jj-janssen-biotech-enter-25m-settlement-over-alleged-remicade-antitrust-scheme/ 2023-03-20T04:01:00+00:00 https://biolegacyresearch.com/novel-schizophrenia-treatment-racks-up-positive-phase-3-numbers/ 2023-03-20T04:01:00+00:00 https://biolegacyresearch.com/biontech-connects-with-oncoc4-to-develop-cancer-treatment/ 2023-03-20T04:01:00+00:00 https://biolegacyresearch.com/cder-flags-enforcement-successes-for-fiscal-2022/ 2023-03-20T04:01:00+00:00 https://biolegacyresearch.com/california-teams-with-civica-rx-to-manufacture-low-cost-insulin/ 2023-03-21T04:01:00+00:00 https://biolegacyresearch.com/phrma-seeks-changes-to-fdas-draft-guidance-on-dosage-labeling/ 2023-03-21T04:01:00+00:00 https://biolegacyresearch.com/fda-considers-biomarker-data-supportive-of-tofersen-approval/ 2023-03-21T04:01:00+00:00 https://biolegacyresearch.com/icer-panel-leqembi-needs-more-long-term-data-to-prove-itself/ 2023-03-21T04:01:00+00:00 https://biolegacyresearch.com/fda-accuses-pg-of-submitting-contradictory-ingredient-information-on-nyquil/ 2023-03-21T04:01:00+00:00 https://biolegacyresearch.com/moderna-ceo-hammered-over-intended-vaccine-price-increase-at-senate-hearing/ 2023-03-23T04:01:00+00:00 https://biolegacyresearch.com/phrma-shares-thoughts-on-developing-emergency-clinical-trial-infrastructure/ 2023-03-23T04:01:00+00:00 https://biolegacyresearch.com/fda-issues-warning-letter-to-arkansas-drug-manufacturer/ 2023-03-23T04:01:00+00:00 https://biolegacyresearch.com/fda-advisory-committee-suggests-accelerated-approval-for-biogens-tofersen/ 2023-03-23T04:01:00+00:00 https://biolegacyresearch.com/abbvie-hits-snag-for-parkinsons-disease-candidate/ 2023-03-23T04:01:00+00:00 https://biolegacyresearch.com/fda-framework-will-explore-digital-health-technology-in-regulatory-decision-making/ 2023-03-23T04:01:00+00:00 https://biolegacyresearch.com/ftc-files-amicus-brief-supporting-parkinsons-drug-competition/ 2023-03-23T04:01:00+00:00 https://biolegacyresearch.com/uk-proposes-sweeping-changes-to-rules-governing-clinical-trials/ 2023-03-24T04:01:00+00:00 https://biolegacyresearch.com/fda-guidance-advises-rcts-for-oncology-drugs-seeking-accelerated-approval/ 2023-03-27T04:01:00+00:00 https://biolegacyresearch.com/incyte-gets-complete-response-letter-for-jakafi-extended-release-tablets/ 2023-03-27T04:01:00+00:00 https://biolegacyresearch.com/ich-finalizes-s12-guideline-covering-gene-therapy-products/ 2023-03-27T04:01:00+00:00 https://biolegacyresearch.com/fdas-2024-budget-request-seeks-funds-to-tackle-drug-and-device-shortages/ 2023-03-27T04:01:00+00:00 https://biolegacyresearch.com/drug-supply-chain-is-vulnerable-to-threats-says-senate-committee/ 2023-03-27T04:01:00+00:00 https://biolegacyresearch.com/california-judge-says-zantac-single-plaintiff-lawsuit-may-proceed/ 2023-03-27T04:01:00+00:00 https://biolegacyresearch.com/lilly-and-roche-collaborate-on-blood-test-for-early-detection-of-alzheimers/ 2023-03-27T04:01:00+00:00 https://biolegacyresearch.com/fda-generics-program-resumes-in-person-meetings/ 2023-03-28T04:01:00+00:00 https://biolegacyresearch.com/bipartisan-pbm-transparency-act-advances-out-of-committee/ 2023-03-28T04:01:00+00:00 https://biolegacyresearch.com/ema-highlights-trial-innovation-real-world-data-advances-in-mid-point-rss-report/ 2023-03-28T04:01:00+00:00 https://biolegacyresearch.com/former-fda-official-says-agency-was-right-to-approve-aduhelm/ 2023-03-28T04:01:00+00:00 https://biolegacyresearch.com/white-house-outlines-new-drug-manufacturing-goals-to-improve-supply-chain/ 2023-03-29T04:01:00+00:00 https://biolegacyresearch.com/califf-defends-against-proposed-cuts-to-fdas-budget-for-fiscal-2024/ 2023-03-29T04:01:00+00:00 https://biolegacyresearch.com/fda-approves-over-the-counter-naloxone-nasal-spray/ 2023-03-29T04:01:00+00:00 https://biolegacyresearch.com/esperion-sues-daiichi-sankyo-over-300m-milestone-payment/ 2023-03-29T04:01:00+00:00 https://biolegacyresearch.com/approved-alzheimers-treatments-ramp-up-research-enthusiasm-experts-say/ 2023-03-30T04:01:00+00:00 https://biolegacyresearch.com/doj-should-scrutinize-pbms-rebates-part-d-bids-experts-tell-congress/ 2023-03-30T04:01:00+00:00 https://biolegacyresearch.com/court-rules-fda-must-divulge-internal-deliberations-on-vandas-hetlioz-snda/ 2023-03-30T04:01:00+00:00 https://biolegacyresearch.com/fda-issues-guidance-on-iso-data-standards-for-medicinal-products/ 2023-03-30T04:01:00+00:00 https://biolegacyresearch.com/cbers-marks-says-products-under-euas-to-stay-available-beyond-end-of-phe/ 2023-03-31T04:01:00+00:00 https://biolegacyresearch.com/interview-fdas-woodcock-on-accelerated-approval-clinical-trial-priorities-patent-reform/ 2023-03-31T17:18:00+00:00 https://biolegacyresearch.com/regulatory-update-april-3-2023/ 2023-03-31T17:23:00+00:00 https://biolegacyresearch.com/prima-system-to-restore-vision-in-macular-degeneration-gets-breakthrough-status/ 2023-03-31T19:15:00+00:00 https://biolegacyresearch.com/u-s-solicitor-general-presses-supreme-court-to-take-up-skinny-labeling-case/ 2023-03-31T20:25:00+00:00 https://biolegacyresearch.com/republican-lawmakers-press-califf-for-answers-about-ongoing-drug-shortages/ 2023-03-31T21:18:00+00:00 https://biolegacyresearch.com/ai-underpins-a-new-generation-of-medical-devices-and-raises-many-questions/ 2023-04-03T17:15:00+00:00 https://biolegacyresearch.com/illumina-to-appeal-ftcs-order-to-divest-liquid-biopsy-maker-grail/ 2023-04-03T19:30:00+00:00 https://biolegacyresearch.com/jury-says-sandoz-owes-39m-for-eyelash-drug-patent-infringement/ 2023-04-03T20:20:00+00:00 https://biolegacyresearch.com/sterility-issues-still-plague-eye-care-drugmaker-in-the-wake-of-two-recalls/ 2023-04-03T21:40:00+00:00 https://biolegacyresearch.com/ifdanews-i-introduces-new-editorial-advisory-board/ 2023-04-04T16:40:00+00:00 https://biolegacyresearch.com/masimo-gains-de-novo-authorization-for-wearable-opioid-overdose-monitor/ 2023-04-04T19:30:00+00:00 https://biolegacyresearch.com/sartorius-to-extend-its-gene-therapy-vector-portfolio-in-2-6b-polyplus-purchase/ 2023-04-04T20:18:00+00:00 https://biolegacyresearch.com/fda-requires-opioids-producers-to-supply-mail-back-envelopes-for-disposal/ 2023-04-04T21:30:00+00:00 https://biolegacyresearch.com/fda-enforcement-actions/ 2023-04-05T17:45:00+00:00 https://biolegacyresearch.com/synovo-production-gets-warning-letter-for-unreported-modifications/ 2023-04-05T17:45:00+00:00 https://biolegacyresearch.com/advanced-accelerator-applications-hit-with-483-for-deficient-procedures/ 2023-04-05T17:45:00+00:00 https://biolegacyresearch.com/defender-sd-manufacturing-hit-for-systems-lapses/ 2023-04-05T17:45:00+00:00 https://biolegacyresearch.com/teva-gets-form-483-for-unknown-residues-quality-lapses/ 2023-04-05T17:45:00+00:00 https://biolegacyresearch.com/omega-packaging-hit-with-form-483-for-inadequate-test-methods-other-lapses/ 2023-04-05T17:45:00+00:00 https://biolegacyresearch.com/advamed-urges-supreme-court-not-to-stifle-innovation-in-two-false-claims-act-cases/ 2023-04-05T19:40:00+00:00 https://biolegacyresearch.com/fda-issues-draft-guidance-on-manufacturing-interruptions-to-reduce-shortages/ 2023-04-05T20:15:00+00:00 https://biolegacyresearch.com/cder-director-cavazzoni-flags-centers-priorities-for-fiscal-2024/ 2023-04-05T21:05:00+00:00 https://biolegacyresearch.com/double-check-facts-and-understand-observations-on-inspection-reports-expert-advises/ 2023-04-06T16:05:00+00:00 https://biolegacyresearch.com/ema-adds-new-elements-to-its-prime-review-pathway/ 2023-04-06T16:10:00+00:00 https://biolegacyresearch.com/arbutus-genevant-allege-patent-infringement-over-pfizer-biontech-vaccine-technology/ 2023-04-06T18:25:00+00:00 https://biolegacyresearch.com/fda-withdraws-makena-approval-effective-immediately/ 2023-04-06T20:15:12+00:00 https://biolegacyresearch.com/former-magellan-executives-charged-with-conspiracy-wire-fraud/ 2023-04-06T20:20:14+00:00 https://biolegacyresearch.com/regulatory-update-april-10-2023/ 2023-04-07T15:55:00+00:00 https://biolegacyresearch.com/challenge-to-minnesotas-free-insulin-law-will-move-forward-federal-court-rules/ 2023-04-07T16:45:31+00:00 https://biolegacyresearch.com/ai-powered-medical-devices-regulating-products-that-continually-change/ 2023-04-07T17:02:24+00:00 https://biolegacyresearch.com/cber-director-highlights-hiring-challenges-other-issues-ahead-for-fiscal-2024/ 2023-04-07T19:35:29+00:00 https://biolegacyresearch.com/abbvie-jj-withdraw-accelerated-approval-of-imbruvica-for-certain-blood-cancers/ 2023-04-07T21:00:30+00:00 https://biolegacyresearch.com/written-procedures-trip-up-drugmakers-most-often-fda-inspection-data-show/ 2023-04-10T17:09:55+00:00 https://biolegacyresearch.com/more-than-half-of-confirmatory-trials-missed-fda-deadlines-researchers-find/ 2023-04-10T17:16:24+00:00 https://biolegacyresearch.com/astrazeneca-shares-benefit-risk-model-to-spur-industry-discussion/ 2023-04-10T19:25:00+00:00 https://biolegacyresearch.com/philips-respironics-sees-second-class-i-recall-of-cpap-bipap-machines/ 2023-04-10T21:00:14+00:00 https://biolegacyresearch.com/drugmakers-call-mifepristone-ruling-a-legal-overstep-of-fda-authority/ 2023-04-10T21:25:36+00:00 https://biolegacyresearch.com/expert-opinion-digital-therapeutics-can-help-meet-mental-health-goals/ 2023-04-11T15:25:51+00:00 https://biolegacyresearch.com/national-emergency-ends-while-hhs-public-health-emergency-declaration-stands/ 2023-04-11T20:10:00+00:00 https://biolegacyresearch.com/fda-launches-pilot-program-to-encourage-new-device-sterilization-methods/ 2023-04-11T21:10:14+00:00 https://biolegacyresearch.com/qa-guidance-gives-risk-based-monitoring-advice-for-sponsors/ 2023-04-11T21:30:19+00:00 https://biolegacyresearch.com/fda-drug-and-device-approval-monthly-roundup/ 2023-04-12T17:55:08+00:00 https://biolegacyresearch.com/califf-says-device-innovations-can-help-stem-opioid-crisis-but-face-obstacles/ 2023-04-12T19:35:13+00:00 https://biolegacyresearch.com/in-a-win-for-moderna-u-s-appeals-court-affirms-arbutus-lnp-patent-is-invalid/ 2023-04-12T19:38:14+00:00 https://biolegacyresearch.com/fda-issues-draft-guidances-on-generic-transdermal-topical-drug-delivery-systems/ 2023-04-12T19:52:15+00:00 https://biolegacyresearch.com/fdas-expedited-review-pathways-to-speed-drug-approvals/ 2023-04-13T17:05:10+00:00 https://biolegacyresearch.com/icer-sickle-cell-gene-therapies-would-be-worth-a-2-million-price-tag/ 2023-04-13T18:40:46+00:00 https://biolegacyresearch.com/fda-advises-on-510k-submissions-for-angioplasty-balloon-and-specialty-catheters/ 2023-04-13T19:40:49+00:00 https://biolegacyresearch.com/bristol-myers-squibb-pfizer-sue-to-block-generic-eliquis/ 2023-04-13T20:35:47+00:00 https://biolegacyresearch.com/white-house-will-seek-emergency-relief-from-supreme-court-on-mifepristone-decision/ 2023-04-13T21:02:37+00:00 https://biolegacyresearch.com/interview-cder-ond-director-stein-on-novel-drugs-expedited-approval-pathways/ 2023-04-14T16:50:34+00:00 https://biolegacyresearch.com/regulatory-update-week-of-april-17-2023/ 2023-04-14T17:45:00+00:00 https://biolegacyresearch.com/regulatory-update-week-of-april-10-2023/ 2023-04-14T17:45:00+00:00 https://biolegacyresearch.com/imdrf-guidances-offer-best-practices-for-cybersecurity-and-personalized-devices/ 2023-04-14T18:55:57+00:00 https://biolegacyresearch.com/ora-needs-new-technology-to-modernize-inspections-and-harmonize-data-leaders-say/ 2023-04-14T20:34:00+00:00 https://biolegacyresearch.com/fda-adcomms-give-thumbs-up-to-rexulti-for-dementia-agitation/ 2023-04-14T21:15:54+00:00 https://biolegacyresearch.com/guest-column-chinas-green-pathway-for-medical-devices/ 2023-04-17T17:25:31+00:00 https://biolegacyresearch.com/fda-issues-crl-to-alvotech-over-bla-for-humira-biosimilar-candidate/ 2023-04-17T17:30:38+00:00 https://biolegacyresearch.com/modernas-mrna-vaccine-keytruda-nearly-halves-melanoma-recurrence-death/ 2023-04-17T19:45:00+00:00 https://biolegacyresearch.com/new-research-shows-wireless-medical-devices-highly-vulnerable-to-malicious-activity/ 2023-04-17T19:50:00+00:00 https://biolegacyresearch.com/merck-expands-immunology-pipeline-with-11-billion-prometheus-purchase/ 2023-04-17T20:50:31+00:00 https://biolegacyresearch.com/legislative-update-week-of-april-17-2023/ 2023-04-18T17:06:09+00:00 https://biolegacyresearch.com/gamida-cell-snags-full-approval-for-stem-cell-product-that-reduces-risk-of-infection/ 2023-04-18T18:55:57+00:00 https://biolegacyresearch.com/woodcock-returning-to-pre-2016-rules-on-mifeprex-would-create-significant-chaos/ 2023-04-18T19:42:49+00:00 https://biolegacyresearch.com/philips-forges-cloud-based-ai-pact-with-aws-for-imaging-software-system/ 2023-04-18T20:51:01+00:00 https://biolegacyresearch.com/warning-letters-trend-toward-component-testing-contractor-oversight-in-2022/ 2023-04-18T21:05:08+00:00 https://biolegacyresearch.com/research-roundup-more-amyloid-depletion-yields-better-cognitive-results-in-alzheimers-trials/ 2023-04-19T17:32:43+00:00 https://biolegacyresearch.com/meeting-planner-week-of-april-17-2023/ 2023-04-19T17:40:49+00:00 https://biolegacyresearch.com/abbott-point-of-care-draws-fda-warning-letter-for-unapproved-device-changes/ 2023-04-19T20:15:48+00:00 https://biolegacyresearch.com/cder-officials-tout-benefits-of-guidance-snapshot-pilot-program/ 2023-04-19T20:34:47+00:00 https://biolegacyresearch.com/califf-in-senate-budget-hearing-fda-needs-authority-to-restrict-new-opioid-approvals/ 2023-04-19T21:50:52+00:00 https://biolegacyresearch.com/fresenius-kabi-infusion-pump-recall-deemed-class-i/ 2023-04-20T17:10:13+00:00 https://biolegacyresearch.com/making-the-cut-to-gain-the-benefits-of-orphan-drug-status/ 2023-04-20T17:15:15+00:00 https://biolegacyresearch.com/fda-approves-first-in-class-antibody-drug-conjugate-for-diffuse-large-b-cell-lymphoma/ 2023-04-20T19:50:12+00:00 https://biolegacyresearch.com/fda-sees-adcomm-push-back-on-long-term-opioid-efficacy-trial-design/ 2023-04-20T20:30:12+00:00 https://biolegacyresearch.com/maker-of-generic-abortion-pill-sues-fda-to-prevent-potential-enforcement-actions/ 2023-04-20T21:55:56+00:00 https://biolegacyresearch.com/moderna-ibm-team-up-to-accelerate-mrna-research-with-quantum-computing-ai/ 2023-04-21T17:35:41+00:00 https://biolegacyresearch.com/more-than-half-of-medicares-popular-drugs-have-low-added-benefit-study-shows/ 2023-04-21T18:20:58+00:00 https://biolegacyresearch.com/ema-adopts-final-ich-s12-covering-nonclinical-bd-studies-for-gene-therapies/ 2023-04-21T19:47:00+00:00 https://biolegacyresearch.com/fda-program-profile-step-program-speeds-technology-to-market/ 2023-04-21T21:00:40+00:00 https://biolegacyresearch.com/avanos-medicals-ballard-access-ventilation-device-recall-labeled-class-i/ 2023-04-24T19:24:31+00:00 https://biolegacyresearch.com/bluebird-amps-up-lovo-cels-regulatory-package-with-bla-priority-review-request/ 2023-04-24T19:26:34+00:00 https://biolegacyresearch.com/fda-and-ftc-focus-on-enforcement-of-connected-medical-devices/ 2023-04-24T19:28:07+00:00 https://biolegacyresearch.com/fda-seeks-comments-on-proposed-consumer-rx-advertising-survey/ 2023-04-24T19:29:26+00:00 https://biolegacyresearch.com/supreme-court-sends-mifepristone-ruling-back-to-appeals-court-for-arguments-in-may/ 2023-04-24T21:25:59+00:00 https://biolegacyresearch.com/legislative-update-week-of-april-24-2023/ 2023-04-25T17:15:54+00:00 https://biolegacyresearch.com/fda-slaps-foghorn-with-another-clinical-hold-on-its-anticancer-line/ 2023-04-25T18:45:47+00:00 https://biolegacyresearch.com/vitamin-d-supports-improved-outcomes-with-opdivo-keytruda-for-melanoma/ 2023-04-25T19:15:51+00:00 https://biolegacyresearch.com/amicus-briefs-in-mifepristone-case-offer-window-into-bitter-fight-ahead/ 2023-04-25T21:35:52+00:00 https://biolegacyresearch.com/florida-files-second-suit-against-fda-for-delaying-states-drug-import-program/ 2023-04-25T22:01:08+00:00 https://biolegacyresearch.com/meeting-planner-week-of-april-24-2023/ 2023-04-26T17:25:55+00:00 https://biolegacyresearch.com/biogen-snags-accelerated-approval-for-als-drug-based-on-biomarker-data/ 2023-04-26T20:05:52+00:00 https://biolegacyresearch.com/fda-lifts-medtronics-2021-insulin-pump-warning-letter/ 2023-04-26T20:12:53+00:00 https://biolegacyresearch.com/new-senate-bill-aims-to-bolster-medicares-ability-to-negotiate-drug-prices/ 2023-04-26T21:48:54+00:00 https://biolegacyresearch.com/eu-proposes-sweeping-new-drug-development-law-pharma-industry-balks/ 2023-04-26T22:05:30+00:00 https://biolegacyresearch.com/eu-device-regulatory-group-issues-best-practices-for-technical-documentation/ 2023-04-27T18:37:11+00:00 https://biolegacyresearch.com/medivance-handed-fda-warning-letter-for-modifying-device-after-clearance/ 2023-04-27T19:10:16+00:00 https://biolegacyresearch.com/voyant-beauty-handed-warning-letter-for-contamination-issues/ 2023-04-27T19:10:17+00:00 https://biolegacyresearch.com/pharmaplast-receives-warning-letter-for-product-testing-equipment-cleaning-issues/ 2023-04-27T19:10:18+00:00 https://biolegacyresearch.com/ema-to-resume-trial-data-publication-efforts-in-september/ 2023-04-27T19:24:15+00:00 https://biolegacyresearch.com/akorn-pharmaceuticals-recalls-unexpired-drugs-as-it-completes-final-shutdown/ 2023-04-27T19:55:36+00:00 https://biolegacyresearch.com/chmp-endorses-adult-rsv-vaccine-six-other-new-drugs-in-april-meeting/ 2023-04-27T20:56:00+00:00 https://biolegacyresearch.com/regulatory-update-week-of-april-24-2023/ 2023-04-28T17:21:40+00:00 https://biolegacyresearch.com/illumina-dna-sequencing-devices-found-vulnerable-to-hacking/ 2023-04-28T18:47:50+00:00 https://biolegacyresearch.com/takeda-gets-thumbs-up-on-subcutaneous-entyvio-bla/ 2023-04-28T18:48:20+00:00 https://biolegacyresearch.com/expert-insights-on-process-validation-for-devicemakers/ 2023-04-28T20:26:47+00:00 https://biolegacyresearch.com/fda-panel-votes-to-limit-lynparza-with-zytiga-to-certain-prostate-cancer-patients/ 2023-04-28T22:49:51+00:00 https://biolegacyresearch.com/fda-credibility-among-public-is-under-threat-says-regulatory-expert/ 2023-05-01T17:15:04+00:00 https://biolegacyresearch.com/uk-to-extend-acceptance-of-ce-marked-devices-for-5-years/ 2023-05-01T19:44:27+00:00 https://biolegacyresearch.com/ascendis-hit-with-crl-over-variability-in-delivered-dose-in-drug-device-combo/ 2023-05-01T20:36:33+00:00 https://biolegacyresearch.com/astellas-snaps-up-iveric-bio-and-late-stage-eye-disease-therapy/ 2023-05-01T21:15:00+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-on-nicotine-replacement-therapies/ 2023-05-01T21:35:33+00:00 https://biolegacyresearch.com/legislative-update-week-of-may-1-2023/ 2023-05-02T17:51:04+00:00 https://biolegacyresearch.com/after-delays-avadel-gets-approval-orphan-drug-exclusivity-for-narcolepsy-drug/ 2023-05-02T19:22:35+00:00 https://biolegacyresearch.com/breakthrough-device-program-supports-innovation-but-not-speed/ 2023-05-02T20:15:27+00:00 https://biolegacyresearch.com/state-ags-press-case-for-full-coverage-of-antiamyloid-alzheimers-therapies/ 2023-05-02T21:22:50+00:00 https://biolegacyresearch.com/guidance-explains-how-drug-and-device-sponsors-should-conduct-dcts/ 2023-05-02T22:00:26+00:00 https://biolegacyresearch.com/meeting-planner-week-of-may-1-2023/ 2023-05-03T18:02:28+00:00 https://biolegacyresearch.com/federal-lawsuit-alleges-fda-revealed-trade-secrets-to-generics-manufacturers/ 2023-05-03T19:27:40+00:00 https://biolegacyresearch.com/fda-adopts-revised-ich-guideline-on-quality-risk-management/ 2023-05-03T20:20:53+00:00 https://biolegacyresearch.com/advocacy-groups-clash-on-right-to-repair-medical-devices/ 2023-05-03T20:55:00+00:00 https://biolegacyresearch.com/number-of-overdue-priority-review-andas-dips-in-fy-2023/ 2023-05-03T21:25:00+00:00 https://biolegacyresearch.com/omega-packaging-fails-to-respond-to-483-gets-warning-letter-for-ethanol-issues/ 2023-05-04T19:29:03+00:00 https://biolegacyresearch.com/aps-pharmacy-receives-warning-letter-following-unaddressed-483-concerns/ 2023-05-04T19:29:37+00:00 https://biolegacyresearch.com/indian-otc-manufacturer-hit-with-warning-letter-after-review-of-company-records/ 2023-05-04T19:30:12+00:00 https://biolegacyresearch.com/lupin-hit-with-483-for-allowing-deficient-batches-in-u-s-market-other-repeat-lapses/ 2023-05-04T19:31:51+00:00 https://biolegacyresearch.com/gsk-wins-rsv-vaccine-race-but-pfizer-may-be-close-behind/ 2023-05-04T20:00:00+00:00 https://biolegacyresearch.com/fda-publishes-mapps-update-on-bioequivalence-studies-with-clinical-endpoints/ 2023-05-04T20:44:46+00:00 https://biolegacyresearch.com/lilly-will-go-for-full-approval-on-alzheimers-drug-despite-high-adverse-event-rate/ 2023-05-04T21:44:22+00:00 https://biolegacyresearch.com/in-senate-hearing-califf-pushes-for-enhanced-supply-chain-authority/ 2023-05-04T22:30:32+00:00 https://biolegacyresearch.com/regulatory-update-week-of-may-1-2023/ 2023-05-05T17:30:45+00:00 https://biolegacyresearch.com/fdas-intended-use-of-new-authority-for-device-off-label-enforcement-unclear/ 2023-05-05T18:07:12+00:00 https://biolegacyresearch.com/ema-seeks-public-comment-on-new-trial-data-transparency-rules/ 2023-05-05T19:00:37+00:00 https://biolegacyresearch.com/stryker-hit-with-fresh-probe-into-potential-foreign-bribery-violations/ 2023-05-05T20:11:29+00:00 https://biolegacyresearch.com/fda-final-guidance-details-pdufa-vii-fee-program-assessment-changes/ 2023-05-05T20:50:20+00:00 https://biolegacyresearch.com/gao-federal-funding-of-clinical-trials-frequently-unreported-in-patent-applications/ 2023-05-08T20:17:27+00:00 https://biolegacyresearch.com/eu-notified-bodies-can-use-new-form-letter-to-advise-devicemakers-on-status/ 2023-05-08T20:17:54+00:00 https://biolegacyresearch.com/mdsap-qms-implementation-plan-highlights-ongoing-assessments-and-improvements/ 2023-05-08T20:57:10+00:00 https://biolegacyresearch.com/u-s-obesity-rate-may-be-the-undoing-of-perrigos-otc-birth-control-pill/ 2023-05-08T21:49:15+00:00 https://biolegacyresearch.com/medtech-leaders-comment-on-eto-as-a-device-sterilization-method-at-epa-hearing/ 2023-05-08T21:49:41+00:00 https://biolegacyresearch.com/legislative-update-week-of-may-8-2023/ 2023-05-09T17:35:16+00:00 https://biolegacyresearch.com/interview-director-kopcha-says-supply-chain-quality-metrics-top-opqs-priority-list/ 2023-05-09T20:20:44+00:00 https://biolegacyresearch.com/vha-fda-and-mhra-team-up-for-ai-ml-cardiovascular-challenge/ 2023-05-09T20:40:00+00:00 https://biolegacyresearch.com/fda-final-guidance-on-glycerin-high-risk-drug-components-aims-to-prevent-poisonings/ 2023-05-09T21:05:22+00:00 https://biolegacyresearch.com/mdic-details-risk-based-capa-process-in-new-white-paper-focused-on-pilot/ 2023-05-09T21:12:24+00:00 https://biolegacyresearch.com/meeting-planner-week-of-may-8-2023/ 2023-05-10T17:28:10+00:00 https://biolegacyresearch.com/sun-pharma-violates-consent-decree-halts-shipments-to-u-s-under-fda-order/ 2023-05-10T19:54:45+00:00 https://biolegacyresearch.com/u-s-government-loses-landmark-gilead-hiv-drug-patent-case/ 2023-05-10T21:40:52+00:00 https://biolegacyresearch.com/advisory-committee-unanimously-supports-perrigos-otc-bid-for-oral-contraceptive/ 2023-05-10T21:45:18+00:00 https://biolegacyresearch.com/senators-grill-drugmakers-pbms-in-hearing-on-lowering-insulin-prices/ 2023-05-10T22:08:09+00:00 https://biolegacyresearch.com/fdas-april-2023-new-drug-approvals/ 2023-05-11T18:29:41+00:00 https://biolegacyresearch.com/lilly-slapped-with-183-million-treble-false-claims-act-penalty/ 2023-05-11T19:26:05+00:00 https://biolegacyresearch.com/fda-approves-first-treatment-for-agitation-associated-with-alzheimers-dementia/ 2023-05-11T20:12:53+00:00 https://biolegacyresearch.com/senate-help-committee-votes-to-send-four-drug-reform-bills-to-full-chamber/ 2023-05-11T22:00:15+00:00 https://biolegacyresearch.com/ars-neffy-gets-advisory-committee-thumbs-up-to-replace-epipen-injection/ 2023-05-12T15:42:59+00:00 https://biolegacyresearch.com/regulatory-update-week-of-may-8-2023/ 2023-05-12T17:35:00+00:00 https://biolegacyresearch.com/fda-seeks-feedback-on-ai-and-machine-learning-in-drug-development/ 2023-05-12T18:30:00+00:00 https://biolegacyresearch.com/philips-to-pay-62-million-to-resolve-charges-of-violating-u-s-law-in-china/ 2023-05-12T19:30:17+00:00 https://biolegacyresearch.com/first-nonhormonal-treatment-for-menopause-hot-flashes-wins-fda-approval/ 2023-05-12T20:30:35+00:00 https://biolegacyresearch.com/despite-data-concerns-fda-adcomm-supports-accelerated-approval-for-gene-therapy/ 2023-05-15T15:42:20+00:00 https://biolegacyresearch.com/benefits-of-priority-review-include-speedier-track-potential-vouchers/ 2023-05-15T17:00:58+00:00 https://biolegacyresearch.com/eu-commission-template-guides-reports-on-device-clinical-trial-results/ 2023-05-15T18:00:00+00:00 https://biolegacyresearch.com/device-industry-sees-surge-in-trade-agreement-false-claims-litigation/ 2023-05-15T21:01:36+00:00 https://biolegacyresearch.com/most-class-i-device-recall-notices-lack-key-identification-numbers-study-says/ 2023-05-15T21:40:42+00:00 https://biolegacyresearch.com/legislative-update-week-of-may-15-2023/ 2023-05-16T17:13:36+00:00 https://biolegacyresearch.com/ftc-files-lawsuit-to-block-amgens-acquisition-of-horizon-amgen-fires-back/ 2023-05-16T20:12:33+00:00 https://biolegacyresearch.com/quanta-sec-agree-to-settle-covid-19-treatment-trial-fraud-charges/ 2023-05-16T20:47:32+00:00 https://biolegacyresearch.com/fda-highlights-positive-data-for-pfizers-rsv-vaccine-in-adcomm-briefing-document/ 2023-05-16T21:15:00+00:00 https://biolegacyresearch.com/philips-concludes-recalled-sleep-therapy-devices-not-likely-to-cause-harm/ 2023-05-16T21:48:03+00:00 https://biolegacyresearch.com/meeting-planner-week-of-may-15-2023/ 2023-05-17T16:42:26+00:00 https://biolegacyresearch.com/digging-into-digital-therapeutics-trials-advice-for-sites-and-sponsors/ 2023-05-17T17:36:48+00:00 https://biolegacyresearch.com/two-new-draft-guidances-clarify-requirements-for-pediatric-drug-development/ 2023-05-17T20:06:57+00:00 https://biolegacyresearch.com/califf-diabetes-weight-loss-alzheimers-drugs-could-be-major-game-changers/ 2023-05-17T20:50:00+00:00 https://biolegacyresearch.com/warning-letter-cites-eye-drop-manufacturer-for-lack-of-sterile-environment/ 2023-05-17T21:12:01+00:00 https://biolegacyresearch.com/eu-gmp-report-may-2023/ 2023-05-18T18:24:23+00:00 https://biolegacyresearch.com/cdrhs-shuren-aims-to-put-u-s-at-top-of-novel-device-launches/ 2023-05-18T20:00:00+00:00 https://biolegacyresearch.com/ftc-deepens-probe-of-pbms-house-advances-pricing-transparency-bill/ 2023-05-18T20:30:00+00:00 https://biolegacyresearch.com/scotus-denies-amgens-bid-to-revive-repatha-patents/ 2023-05-18T21:00:22+00:00 https://biolegacyresearch.com/ema-publishes-10-point-guideline-on-preventing-drug-shortages/ 2023-05-18T21:30:00+00:00 https://biolegacyresearch.com/regulatory-update-week-of-may-15-2023/ 2023-05-19T16:49:40+00:00 https://biolegacyresearch.com/fda-advisory-committee-supports-pfizers-maternal-rsv-vaccine/ 2023-05-19T17:40:38+00:00 https://biolegacyresearch.com/study-of-2-types-of-cardiac-stents-shows-no-difference-in-outcomes/ 2023-05-19T18:11:01+00:00 https://biolegacyresearch.com/fda-clears-heart-brain-and-pregnancy-related-products/ 2023-05-19T19:30:07+00:00 https://biolegacyresearch.com/cber-cder-directors-review-priorities-and-challenges-at-fdli-annual-conference/ 2023-05-19T20:46:11+00:00 https://biolegacyresearch.com/advisory-committee-turns-down-intercepts-bid-for-nash-drug/ 2023-05-22T17:04:26+00:00 https://biolegacyresearch.com/anti-kickback-stark-violations-dominated-2022-device-false-claims-suits/ 2023-05-22T17:09:15+00:00 https://biolegacyresearch.com/precision-lens-ordered-to-pay-487-million-for-violation-of-false-claims-act/ 2023-05-22T18:46:58+00:00 https://biolegacyresearch.com/ftc-increases-scrutiny-of-security-and-use-of-health-data-collected-by-apps-devices/ 2023-05-22T21:01:14+00:00 https://biolegacyresearch.com/centaur-pharmaceuticals-gets-483-for-hiding-shredding-documents-other-quality-lapses/ 2023-05-22T21:11:07+00:00 https://biolegacyresearch.com/legislative-update-week-of-may-22-2023/ 2023-05-23T18:06:31+00:00 https://biolegacyresearch.com/using-audit-findings-to-drive-quality/ 2023-05-23T19:48:19+00:00 https://biolegacyresearch.com/ironwood-to-buy-vectivbio-for-1-15-billion-expanding-gastro-portfolio/ 2023-05-23T20:25:07+00:00 https://biolegacyresearch.com/teva-hit-with-class-action-suit-for-allegedly-blocking-generic-inhalers/ 2023-05-23T20:55:00+00:00 https://biolegacyresearch.com/republicans-renew-call-for-reciprocity-in-fdas-approval-process/ 2023-05-23T21:30:00+00:00 https://biolegacyresearch.com/meeting-planner-week-of-may-22-2023/ 2023-05-24T17:06:37+00:00 https://biolegacyresearch.com/ich-advances-draft-guideline-on-good-clinical-practice/ 2023-05-24T19:08:18+00:00 https://biolegacyresearch.com/fda-advises-on-using-generally-accepted-scientific-knowledge-in-applications/ 2023-05-24T20:50:07+00:00 https://biolegacyresearch.com/indian-drugmaker-draws-two-fda-warning-letters-over-untested-glycerin/ 2023-05-24T21:15:00+00:00 https://biolegacyresearch.com/janssen-prevails-in-battle-with-mylan-over-schizophrenia-drug-patent/ 2023-05-24T21:25:19+00:00 https://biolegacyresearch.com/research-roundup-may-2023/ 2023-05-25T19:03:08+00:00 https://biolegacyresearch.com/integra-lifesciences-recalls-all-products-made-in-boston-in-past-five-years/ 2023-05-25T19:50:00+00:00 https://biolegacyresearch.com/patent-board-sides-with-spectrum-issues-sanctions-against-longhorn-vaccines/ 2023-05-25T20:11:57+00:00 https://biolegacyresearch.com/lumanlab-university-researchers-partner-on-ai-to-detect-and-assess-autism/ 2023-05-25T20:20:07+00:00 https://biolegacyresearch.com/fda-guidance-roundup/ 2023-05-25T21:49:27+00:00 https://biolegacyresearch.com/regulatory-update-week-of-may-22-2023/ 2023-05-26T17:00:55+00:00 https://biolegacyresearch.com/magi-east-2023-innovation-adoption-takes-too-long-getz-says/ 2023-05-26T18:00:58+00:00 https://biolegacyresearch.com/neuralink-announces-first-in-human-clinical-trial-of-bci-device/ 2023-05-26T19:01:25+00:00 https://biolegacyresearch.com/fda-eagerly-awaits-valid-act-authority-for-lab-developed-tests/ 2023-05-26T19:30:18+00:00 https://biolegacyresearch.com/apellis-wave-drop-als-trials-after-disappointing-results/ 2023-05-26T19:50:00+00:00 https://biolegacyresearch.com/legislative-update-week-of-may-29-2023/ 2023-05-30T17:53:23+00:00 https://biolegacyresearch.com/eu-to-run-pilot-to-test-real-time-generated-human-medicine-product-information/ 2023-05-30T19:59:18+00:00 https://biolegacyresearch.com/amended-pbm-reform-bill-clears-house-energy-and-commerce-committee/ 2023-05-30T20:37:04+00:00 https://biolegacyresearch.com/fda-proposes-rule-to-replace-medication-guides-with-single-page-info-sheets/ 2023-05-30T20:37:48+00:00 https://biolegacyresearch.com/chmp-recommends-pulling-novartis-sickle-cell-drug-approves-two-other-drugs/ 2023-05-30T20:44:41+00:00 https://biolegacyresearch.com/data-driven-science-how-ai-and-open-data-will-revolutionize-scientific-discovery/ 2023-05-31T17:58:00+00:00 https://biolegacyresearch.com/industry-shares-early-take-on-fdas-draft-decentralized-trial-guidance/ 2023-05-31T18:05:28+00:00 https://biolegacyresearch.com/meeting-planner-week-of-may-29-2023/ 2023-05-31T18:22:01+00:00 https://biolegacyresearch.com/program-offers-devicemakers-up-to-300k-for-using-advanced-technologies/ 2023-05-31T20:08:42+00:00 https://biolegacyresearch.com/fda-updating-warnings-to-improve-safe-use-of-prescription-stimulants-used-to-treat-adhd-and-other-conditions/ 2023-05-31T13:57:27+00:00 https://biolegacyresearch.com/adverse-events-show-slight-rise-in-fda-surveillance-epidemiology-annual-report/ 2023-05-31T21:18:43+00:00 https://biolegacyresearch.com/fda-adds-virtual-component-to-face-to-face-industry-meetings/ 2023-06-01T18:51:56+00:00 https://biolegacyresearch.com/sea-long-medical-systems-warned-for-unapproved-modifications/ 2023-06-01T19:40:00+00:00 https://biolegacyresearch.com/novartis-483-cites-missing-calibration-verification-information/ 2023-06-01T19:40:00+00:00 https://biolegacyresearch.com/maiden-biosciences-gets-483-for-quality-system-lapses/ 2023-06-01T19:40:00+00:00 https://biolegacyresearch.com/fda-knocks-ward-photonics-for-complaint-investigation-lapses/ 2023-06-01T19:40:00+00:00 https://biolegacyresearch.com/fda-cites-repeated-procedure-and-document-issues-at-theweb2u/ 2023-06-01T19:40:00+00:00 https://biolegacyresearch.com/fda-adds-to-migraine-drug-advice-with-guidance-covering-preventive-treatments/ 2023-06-01T20:28:18+00:00 https://biolegacyresearch.com/cms-says-it-will-cover-antiamyloid-antibodies-with-final-fda-approval/ 2023-06-01T21:00:39+00:00 https://biolegacyresearch.com/scotus-sends-false-claims-drug-pricing-case-back-to-lower-court/ 2023-06-01T21:41:20+00:00 https://biolegacyresearch.com/regulatory-update-week-of-may-29-2023/ 2023-06-02T17:47:38+00:00 https://biolegacyresearch.com/fda-says-devicemakers-should-prepare-for-potential-hurricane-disruptions/ 2023-06-02T17:47:40+00:00 https://biolegacyresearch.com/fda-issues-development-program-guidances-to-assist-drug-device-sponsors/ 2023-06-02T17:47:42+00:00 https://biolegacyresearch.com/fda-denies-akebias-vadadustat-appeal-but-suggests-a-path-forward/ 2023-06-02T19:20:47+00:00 https://biolegacyresearch.com/fda-seeks-comments-on-greater-access-to-medical-technologies-at-home/ 2023-06-02T20:00:45+00:00 https://biolegacyresearch.com/drug-shortages-hit-a-five-year-high-with-no-end-in-sight/ 2023-06-05T18:39:36+00:00 https://biolegacyresearch.com/legislative-update-week-of-june-5-2023/ 2023-06-05T19:29:26+00:00 https://biolegacyresearch.com/fda-excludes-drugs-in-short-supply-from-intas-import-alert/ 2023-06-05T20:33:24+00:00 https://biolegacyresearch.com/novo-nordisk-buying-controlling-stake-in-biocorp-for-its-smart-injector-pen/ 2023-06-05T20:35:02+00:00 https://biolegacyresearch.com/cbers-marks-shares-details-on-pilot-for-rare-disease-gene-therapies/ 2023-06-05T21:46:05+00:00 https://biolegacyresearch.com/fda-confirms-its-cover-letter-attachments-for-generic-submissions-are-voluntary/ 2023-06-06T18:31:55+00:00 https://biolegacyresearch.com/best-practices-for-pharma-process-validation/ 2023-06-06T19:00:00+00:00 https://biolegacyresearch.com/fda-calls-for-public-comment-on-revised-draft-of-gcp-guideline/ 2023-06-06T20:22:52+00:00 https://biolegacyresearch.com/merck-sues-u-s-government-over-ira-constitutionality/ 2023-06-06T20:50:11+00:00 https://biolegacyresearch.com/fda-moves-ahead-with-pdufa-vii-commitments-on-real-world-evidence/ 2023-06-06T21:15:00+00:00 https://biolegacyresearch.com/meeting-planner-week-of-june-5-2023/ 2023-06-07T17:00:04+00:00 https://biolegacyresearch.com/moderna-pfizer-sued-by-promosome-over-covid-19-patent-infringement/ 2023-06-07T20:37:00+00:00 https://biolegacyresearch.com/first-of-its-kind-covid-19-home-test-gets-fda-authorization/ 2023-06-07T21:00:00+00:00 https://biolegacyresearch.com/mislabeled-device-unreported-deaths-draw-fda-warning-letter-for-irhythm/ 2023-06-07T21:40:35+00:00 https://biolegacyresearch.com/fda-signals-support-for-leqembi-and-nirsevimab-in-upcoming-adcomms/ 2023-06-07T22:18:53+00:00 https://biolegacyresearch.com/fda-drug-and-device-approvals-may-2023/ 2023-06-08T17:33:41+00:00 https://biolegacyresearch.com/fda-denies-intarcias-request-to-alter-adcomm-procedures-for-diabetes-treatment/ 2023-06-08T20:57:33+00:00 https://biolegacyresearch.com/lilly-appeals-183m-false-claims-hit-sees-new-rico-suit-for-bladder-cancer-drug/ 2023-06-08T21:16:51+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-on-drug-drug-interaction-studies-for-oral-contraceptives/ 2023-06-08T21:20:00+00:00 https://biolegacyresearch.com/astrazeneca-rsv-preventive-gets-nearly-unanimous-adcomm-recommendation/ 2023-06-08T21:38:17+00:00 https://biolegacyresearch.com/fda-should-strengthen-its-policy-for-withdrawing-drug-approval-researchers-say/ 2023-06-09T15:33:08+00:00 https://biolegacyresearch.com/fda-guidance-outlines-gdufa-iii-fee-program-changes/ 2023-06-09T17:55:59+00:00 https://biolegacyresearch.com/regulatory-update-week-of-june-5-2023/ 2023-06-09T19:00:16+00:00 https://biolegacyresearch.com/from-phones-that-act-like-stethoscopes-to-vr-surgery-device-innovations-abound/ 2023-06-09T21:05:31+00:00 https://biolegacyresearch.com/adcomms-unanimous-endorsement-sets-leqembi-up-for-full-fda-approval/ 2023-06-09T21:26:18+00:00 https://biolegacyresearch.com/novartis-to-acquire-chinook-therapeutics-for-3-5-b-for-its-two-kidney-disease-candidates/ 2023-06-12T15:28:48+00:00 https://biolegacyresearch.com/fda-congress-and-the-white-house-struggle-to-reduce-drug-shortages/ 2023-06-12T15:33:53+00:00 https://biolegacyresearch.com/legislative-update-week-of-june-12-2023/ 2023-06-12T17:00:18+00:00 https://biolegacyresearch.com/erectile-dysfunction-gel-that-works-in-10-minutes-gets-fda-otc-marketing-authorization/ 2023-06-12T17:27:37+00:00 https://biolegacyresearch.com/ira-imposes-unconstitutional-price-controls-chambers-of-commerce-claim-in-federal-suit/ 2023-06-12T18:01:06+00:00 https://biolegacyresearch.com/consider-regulators-as-partners-when-preparing-for-drug-development-meetings/ 2023-06-13T18:58:41+00:00 https://biolegacyresearch.com/bearcare-wearable-thermometer-sees-class-i-recall-for-overheating-battery-leakage/ 2023-06-13T20:20:00+00:00 https://biolegacyresearch.com/fda-issues-procedures-for-handling-reclassification-requests/ 2023-06-13T20:40:37+00:00 https://biolegacyresearch.com/new-device-submissions-guidance-adds-ai-ml-nlp-software-considerations/ 2023-06-13T21:12:39+00:00 https://biolegacyresearch.com/cder-experts-to-help-shepherd-rare-disease-drugs-through-arc-approval-process/ 2023-06-13T21:34:18+00:00 https://biolegacyresearch.com/meeting-planner-week-of-june-12-2023/ 2023-06-14T18:43:20+00:00 https://biolegacyresearch.com/pfizer-limits-penicillin-products-in-latest-drug-shortage-development/ 2023-06-14T19:15:00+00:00 https://biolegacyresearch.com/right-to-repair-appeal-briefs-argue-rule-on-copyrights-must-be-reviewed/ 2023-06-14T19:50:00+00:00 https://biolegacyresearch.com/fda-calls-on-xeris-to-correct-misleading-safety-and-efficacy-claims/ 2023-06-14T20:00:00+00:00 https://biolegacyresearch.com/manufacturer-discounts-to-pbms-insurers-soar-researchers-show/ 2023-06-14T20:15:00+00:00 https://biolegacyresearch.com/eu-gmp-report-june-2023/ 2023-06-15T17:12:42+00:00 https://biolegacyresearch.com/states-support-illuminas-appeal-of-ftc-grail-divestment-order/ 2023-06-15T18:09:09+00:00 https://biolegacyresearch.com/linzess-first-drug-to-get-fda-approval-for-pediatric-functional-constipation/ 2023-06-15T18:45:00+00:00 https://biolegacyresearch.com/ocd-motor-threshold-cap-receives-510k-clearance-from-fda/ 2023-06-15T19:15:00+00:00 https://biolegacyresearch.com/congress-should-look-to-manufacturers-to-control-high-drug-prices-pbm-association-says/ 2023-06-15T20:42:40+00:00 https://biolegacyresearch.com/regulatory-update-week-of-june-19-2023/ 2023-06-16T17:32:57+00:00 https://biolegacyresearch.com/five-deaths-draw-partial-clinical-hold-for-ovarian-cancer-trials/ 2023-06-16T18:45:40+00:00 https://biolegacyresearch.com/dont-just-conduct-capa-investigations-expert-says-be-sure-to-document-to-avoid-483s/ 2023-06-16T20:30:14+00:00 https://biolegacyresearch.com/humira-biosimilar-will-hit-market-next-month-at-85-off-abbvies-price/ 2023-06-16T20:55:00+00:00 https://biolegacyresearch.com/pediatric-oncology-trials-need-to-move-faster-fda-and-adcomm-members-agree/ 2023-06-16T21:41:50+00:00 https://biolegacyresearch.com/ai-as-good-as-human-experts-in-identifying-epilepsy-eeg-patterns/ 2023-06-20T17:24:36+00:00 https://biolegacyresearch.com/legislative-update-june-19-2023/ 2023-06-20T18:20:00+00:00 https://biolegacyresearch.com/changes-to-rules-for-ldts-national-drug-code-and-device-qsr-top-fda-regulatory-agenda/ 2023-06-20T19:15:46+00:00 https://biolegacyresearch.com/ira-drug-price-negotiation-violates-constitution-bms-claims/ 2023-06-20T19:35:15+00:00 https://biolegacyresearch.com/better-matching-of-patients-to-oncology-drugs-is-goal-of-new-fda-pilot-project/ 2023-06-20T19:55:19+00:00 https://biolegacyresearch.com/meeting-planner-june-19-2023/ 2023-06-21T17:00:17+00:00 https://biolegacyresearch.com/speedy-risk-based-capa-initiative-is-ready-for-adoption-but-creators-fear-industry-may-shy-away/ 2023-06-21T18:00:00+00:00 https://biolegacyresearch.com/patient-preference-safety-evaluation-bioequivalence-new-guidance-areas-for-ich/ 2023-06-21T19:00:00+00:00 https://biolegacyresearch.com/modernized-clinicaltrials-gov-website-goes-live/ 2023-06-21T20:25:00+00:00 https://biolegacyresearch.com/82-percent-of-essential-medicine-api-makers-are-foreign-says-opq-annual-report/ 2023-06-21T21:00:22+00:00 https://biolegacyresearch.com/otc-monograph-drug-appeal-of-final-order-is-subject-of-fda-guidance/ 2023-06-22T18:36:01+00:00 https://biolegacyresearch.com/research-roundup-june-2023/ 2023-06-22T19:20:31+00:00 https://biolegacyresearch.com/dental-device-firm-draws-warning-letter-for-software-snag/ 2023-06-22T19:50:42+00:00 https://biolegacyresearch.com/industry-ira-complaints-continue-to-mount-as-phrma-and-other-groups-file-suit/ 2023-06-22T20:20:41+00:00 https://biolegacyresearch.com/ftc-slams-district-court-decision-supports-pharmacies-in-bystolic-antitrust-case/ 2023-06-22T20:50:10+00:00 https://biolegacyresearch.com/psychedelic-drug-development-is-subject-of-new-fda-draft-guidance/ 2023-06-23T17:43:12+00:00 https://biolegacyresearch.com/jazz-pharma-sues-fda-claiming-approval-of-avadels-narcolepsy-drug-is-unlawful/ 2023-06-23T19:04:05+00:00 https://biolegacyresearch.com/u-s-government-suing-gilead-for-1-billion-over-hiv-prep-drug-patent-case/ 2023-06-23T19:08:07+00:00 https://biolegacyresearch.com/cms-tries-again-to-speed-breakthrough-device-approvals-with-new-coverage-process/ 2023-06-23T19:39:11+00:00 https://biolegacyresearch.com/legislative-update-week-of-june-26-2023/ 2023-06-26T16:59:54+00:00 https://biolegacyresearch.com/novo-nordisks-oral-semaglutide-sees-15-percent-weight-loss-and-better-diabetes-control/ 2023-06-26T18:54:37+00:00 https://biolegacyresearch.com/ftc-fines-promom-fertility-app-developer-100k-orders-protection-of-consumer-data/ 2023-06-26T18:58:01+00:00 https://biolegacyresearch.com/dscsa-phased-approach-suggested-by-healthcare-distribution-alliance/ 2023-06-26T19:31:20+00:00 https://biolegacyresearch.com/despite-problematic-phase-2-data-cber-director-says-muscular-dystrophy-gene-therapy-deserved-accelerated-approval/ 2023-06-26T20:38:17+00:00 https://biolegacyresearch.com/medical-advances-require-scientific-regulatory-social-and-political-collaboration/ 2023-06-27T17:05:34+00:00 https://biolegacyresearch.com/ema-report-identifies-need-to-anticipate-hasten-agency-led-rwe-generation/ 2023-06-27T18:00:41+00:00 https://biolegacyresearch.com/use-quantitative-information-for-consumer-facing-promotion-fda-guidance-says/ 2023-06-27T18:30:00+00:00 https://biolegacyresearch.com/fda-releases-draft-guidance-on-submission-of-3d-printed-orthopedic-implants/ 2023-06-27T19:00:15+00:00 https://biolegacyresearch.com/who-and-ich-to-collaborate-on-unified-language-for-drugs/ 2023-06-27T19:30:41+00:00 https://biolegacyresearch.com/meeting-planner-week-of-june-26-2023/ 2023-06-28T17:05:56+00:00 https://biolegacyresearch.com/improving-rwd-oncology-study-design-is-goal-of-fda-qcard-initiative/ 2023-06-28T18:00:50+00:00 https://biolegacyresearch.com/compounders-may-not-sell-to-wholesalers-to-qualify-for-503b-exemption/ 2023-06-28T20:58:06+00:00 https://biolegacyresearch.com/eu-medical-associations-warn-of-loss-of-pediatric-devices-under-eu-mdr/ 2023-06-28T22:22:32+00:00 https://biolegacyresearch.com/ultra-rare-bone-disease-therapy-gets-fda-panel-nod-despite-data-concerns/ 2023-06-28T22:40:08+00:00 https://biolegacyresearch.com/import-alert-issued-to-chinese-api-manufacturer/ 2023-06-29T19:08:30+00:00 https://biolegacyresearch.com/years-of-quality-control-lapses-draw-a-form-483-for-abbvie/ 2023-06-29T19:08:59+00:00 https://biolegacyresearch.com/complaint-handling-lapses-get-integrated-orbital-implants-a-form-483/ 2023-06-29T19:09:32+00:00 https://biolegacyresearch.com/philips-slapped-with-form-483-for-mdr-failures/ 2023-06-29T19:09:59+00:00 https://biolegacyresearch.com/abbott-capas-lack-adequate-documentation-fda-483-says/ 2023-06-29T19:10:25+00:00 https://biolegacyresearch.com/ftc-and-doj-propose-rule-to-require-more-info-before-mergers-and-acquisitions/ 2023-06-29T20:19:33+00:00 https://biolegacyresearch.com/lilly-acquires-biopharm-sigilon-to-develop-type-1-diabetes-treatments/ 2023-06-29T21:05:34+00:00 https://biolegacyresearch.com/fda-finalizes-guidance-on-chronic-rhinosinusitis-with-nasal-polyps-drug-trials/ 2023-06-29T21:32:20+00:00 https://biolegacyresearch.com/epa-rule-to-limit-ethylene-oxide-will-also-limit-access-to-medical-care-industry-says/ 2023-06-29T22:03:14+00:00 https://biolegacyresearch.com/regulatory-update-week-of-june-26-2023/ 2023-06-30T17:00:00+00:00 https://biolegacyresearch.com/using-risk-based-thinking-to-avoid-catastrophic-failures/ 2023-06-30T18:00:50+00:00 https://biolegacyresearch.com/fda-class-i-recall-for-certain-arrow-catheters-that-may-separate-during-use/ 2023-06-30T19:00:51+00:00 https://biolegacyresearch.com/supply-chain-at-risk-in-every-industry-fda-regulates-associate-commissioner-says/ 2023-06-30T19:45:59+00:00 https://biolegacyresearch.com/pre-determined-change-plans-not-needed-for-ai-ml-former-director-at-cdrh-says/ 2023-06-30T20:00:49+00:00 https://biolegacyresearch.com/legislative-update-week-of-july-3-2023/ 2023-07-03T18:11:28+00:00 https://biolegacyresearch.com/expansion-clarification-needed-for-guidance-on-incorporating-coas-into-endpoints/ 2023-07-03T18:45:00+00:00 https://biolegacyresearch.com/fdas-case-for-quality-targets-continuous-improvement-not-just-compliance/ 2023-07-03T19:00:23+00:00 https://biolegacyresearch.com/amgen-and-horizon-file-counterclaim-in-ftc-antitrust-suit/ 2023-07-03T19:15:25+00:00 https://biolegacyresearch.com/cmss-updates-to-ira-guidance-dont-change-big-picture-impact-for-manufacturers/ 2023-07-03T19:30:22+00:00 https://biolegacyresearch.com/meeting-planner-week-of-july-3-2023/ 2023-07-05T18:01:00+00:00 https://biolegacyresearch.com/parkinsons-drug-complete-response-letter-cites-safety-for-one-ingredient/ 2023-07-05T18:30:05+00:00 https://biolegacyresearch.com/ftc-amicus-brief-clarifies-some-antitrust-standards/ 2023-07-05T19:00:28+00:00 https://biolegacyresearch.com/drugmakers-not-ready-for-drug-supply-chain-act-could-cause-shortages-aam-says/ 2023-07-05T19:15:00+00:00 https://biolegacyresearch.com/ai-ml-marketing-information-inaccurate-for-nearly-20-of-devices-study-says/ 2023-07-05T19:30:19+00:00 https://biolegacyresearch.com/fdas-total-product-life-cycle-program-promotes-streamlined-development/ 2023-07-06T17:42:40+00:00 https://biolegacyresearch.com/routine-fda-surveillance-inspections-prioritized-based-on-site-compliance-history/ 2023-07-06T19:10:31+00:00 https://biolegacyresearch.com/ema-opens-comment-on-ich-endorsed-draft-paper-on-rwd-rwe/ 2023-07-06T20:15:00+00:00 https://biolegacyresearch.com/fda-drug-and-device-approvals-june-2023/ 2023-07-06T20:30:00+00:00 https://biolegacyresearch.com/owlets-baby-sock-recovers-from-warning-letter-laser-cleared-for-pediatric-port-wine-stains/ 2023-07-06T21:01:12+00:00 https://biolegacyresearch.com/regulatory-update-week-of-july-3-2023/ 2023-07-07T18:18:36+00:00 https://biolegacyresearch.com/leqembi-wins-full-approval-and-market-edge-with-medicare-coverage/ 2023-07-07T18:19:38+00:00 https://biolegacyresearch.com/minnesotas-rx-law-unconstitutional-aam-says-and-sues-state-ag/ 2023-07-07T19:30:41+00:00 https://biolegacyresearch.com/europe-phasing-out-of-extraordinary-covid-19-regulatory-flexibility/ 2023-07-07T19:45:35+00:00 https://biolegacyresearch.com/novo-nordisk-sues-pharmacies-weight-loss-clinics-for-illegally-selling-semaglutide/ 2023-07-07T20:43:17+00:00 https://biolegacyresearch.com/legislative-update-week-of-july-10-2023/ 2023-07-10T17:32:02+00:00 https://biolegacyresearch.com/u-s-and-india-cooperate-to-stop-illegal-international-drug-shipments/ 2023-07-10T18:00:08+00:00 https://biolegacyresearch.com/draeger-medical-transport-ventilator-sees-fda-class-i-recall/ 2023-07-10T19:00:51+00:00 https://biolegacyresearch.com/coloplast-to-pay-1-3-billion-for-icelandic-fish-skin-wound-care-manufacturer/ 2023-07-10T20:00:21+00:00 https://biolegacyresearch.com/cms-rule-would-pay-340b-hospitals-9-billion-in-owed-reimbursements/ 2023-07-10T20:30:49+00:00 https://biolegacyresearch.com/fda-offers-direction-on-dietary-management-in-iem-drug-trials/ 2023-07-11T20:09:07+00:00 https://biolegacyresearch.com/ema-revises-guidance-for-its-prime-scheme-drug-development-assistance-program/ 2023-07-11T20:35:00+00:00 https://biolegacyresearch.com/two-megadyne-recalls-one-deemed-class-i-for-potential-electric-burns-one-for-risk-of-mild-shock/ 2023-07-11T20:50:00+00:00 https://biolegacyresearch.com/axonics-wins-appeal-against-medtronic-over-nerve-stimulation-patents/ 2023-07-11T21:06:00+00:00 https://biolegacyresearch.com/additional-observations-cited-in-warning-letter-to-outset-medical/ 2023-07-11T21:20:00+00:00 https://biolegacyresearch.com/meeting-planner-week-of-july-10-2023/ 2023-07-12T17:09:32+00:00 https://biolegacyresearch.com/suicide-ideation-risk-prompts-ema-to-review-wegovy-ozempic/ 2023-07-12T18:29:01+00:00 https://biolegacyresearch.com/fdas-clinical-decision-software-guidance-violates-first-amendment-petitioner-says/ 2023-07-12T18:31:09+00:00 https://biolegacyresearch.com/paclitaxel-coated-devices-dont-carry-excess-mortality-risk-fda-says/ 2023-07-12T19:40:33+00:00 https://biolegacyresearch.com/doj-encourages-companies-to-self-disclose-corporate-misconduct/ 2023-07-12T21:00:16+00:00 https://biolegacyresearch.com/thoughts-on-the-implications-of-fda-approval-of-otc-birth-control/ 2023-07-13T18:40:48+00:00 https://biolegacyresearch.com/icer-affirms-sickle-cell-disease-gene-therapies-cost-effective-at-2-million/ 2023-07-13T19:00:32+00:00 https://biolegacyresearch.com/merck-seeks-summary-judgment-in-ira-drug-pricing-suit/ 2023-07-13T20:00:00+00:00 https://biolegacyresearch.com/managing-manufacturing-changes-of-gene-therapy-products-is-focus-of-draft-guidance/ 2023-07-13T20:00:21+00:00 https://biolegacyresearch.com/fda-clarifies-when-its-ok-to-miss-postmarketing-requirement-milestones/ 2023-07-13T20:01:21+00:00 https://biolegacyresearch.com/regulatory-update-week-of-july-10-2023/ 2023-07-14T17:40:59+00:00 https://biolegacyresearch.com/ftc-ponders-issuing-warning-statement-to-pbms/ 2023-07-14T17:55:57+00:00 https://biolegacyresearch.com/preliminary-injunction-sought-by-chambers-of-commerce-in-ira-drug-pricing-suit/ 2023-07-14T19:25:06+00:00 https://biolegacyresearch.com/hhs-secretary-cautions-industry-on-covid-19-vaccine-prices/ 2023-07-14T19:30:53+00:00 https://biolegacyresearch.com/senators-allege-lillys-promised-insulin-cap-not-in-effect-everywhere/ 2023-07-14T19:45:24+00:00 https://biolegacyresearch.com/regulatory-update-week-of-july-24-2023/ 2023-07-28T18:50:04+00:00 https://biolegacyresearch.com/fda-plans-fiscal-2024-rules-for-clinical-pharmacology-importers-dtc-advertising/ 2023-07-28T20:09:40+00:00 https://biolegacyresearch.com/senate-committee-marks-up-pbm-bill-paves-way-for-full-chamber-consideration/ 2023-07-28T20:25:00+00:00 https://biolegacyresearch.com/abbott-abiomed-ge-healthcare-see-recalls-for-cardiac-devices-deemed-class-i/ 2023-07-28T20:30:00+00:00 https://biolegacyresearch.com/biogen-picks-up-reata-for-7-3b-while-alexion-gets-pfizer-programs-for-1b/ 2023-07-28T20:35:00+00:00 https://biolegacyresearch.com/sponsors-share-perspectives-on-patient-experience-data-at-fdas-request/ 2023-07-31T19:08:52+00:00 https://biolegacyresearch.com/cder-ema-collaborate-on-quality-fda-swissmedic-enter-inspection-agreement/ 2023-07-31T19:25:00+00:00 https://biolegacyresearch.com/legislative-update-week-of-july-31-2023/ 2023-07-31T19:55:00+00:00 https://biolegacyresearch.com/complete-response-letter-sent-to-citius-for-its-lymphoma-drug-lymphir/ 2023-07-31T20:10:11+00:00 https://biolegacyresearch.com/in-latest-340b-program-skirmish-phrma-sues-louisiana-over-drug-discount-law/ 2023-07-31T20:40:00+00:00 https://biolegacyresearch.com/breaking-down-the-draft-of-ich-e6r3/ 2023-08-01T18:15:06+00:00 https://biolegacyresearch.com/23000-infusion-pumps-recalled-by-baxter-for-false-alarms-now-deemed-class-i/ 2023-08-01T18:15:50+00:00 https://biolegacyresearch.com/where-design-control-meets-risk-management/ 2023-08-01T18:16:58+00:00 https://biolegacyresearch.com/510-million-from-astrazeneca-settles-cancer-drug-patent-lawsuits-with-bms-ono/ 2023-08-01T19:18:37+00:00 https://biolegacyresearch.com/mdr-ivdr-applications-and-certificates-increasing-in-eu/ 2023-08-01T20:37:04+00:00 https://biolegacyresearch.com/industry-feedback-fdas-dct-guidance-lacks-depth-on-oversight-task-log/ 2023-08-02T17:46:21+00:00 https://biolegacyresearch.com/fda-and-dea-ask-adhd-drugmakers-to-increase-production/ 2023-08-02T17:46:47+00:00 https://biolegacyresearch.com/meeting-planner-week-of-july-31-2023/ 2023-08-02T19:00:28+00:00 https://biolegacyresearch.com/draft-guidance-updates-pathway-for-hiv-drugs-to-be-distributed-outside-the-u-s/ 2023-08-02T20:08:59+00:00 https://biolegacyresearch.com/hybrid-in-person-virtual-adcomms-may-be-coming-says-fdas-chief-scientist/ 2023-08-02T21:17:18+00:00 https://biolegacyresearch.com/form-483-lapses-identified-at-catalent-facility-net-regenerons-eylea-crl/ 2023-08-03T19:23:44+00:00 https://biolegacyresearch.com/form-483-stryker-dinged-for-failure-to-make-medical-device-reports/ 2023-08-03T19:27:07+00:00 https://biolegacyresearch.com/form-483-poor-aseptic-procedures-and-dirty-bathrooms-get-iso-tex-drugmaker-cited/ 2023-08-03T19:28:57+00:00 https://biolegacyresearch.com/recall-cardiac-panels-could-cause-delayed-diagnosis-or-missed-myocardial-infarction/ 2023-08-03T19:29:32+00:00 https://biolegacyresearch.com/warning-letter-fda-warns-company-that-no-longer-manufacturers-drugs/ 2023-08-03T19:30:21+00:00 https://biolegacyresearch.com/cdrh-is-setting-a-new-normal-for-conducting-business-post-pandemic/ 2023-08-04T18:31:36+00:00 https://biolegacyresearch.com/fda-finding-of-er-lamotrigene-bioequivalence-opens-doors-for-more-generics/ 2023-08-04T18:36:45+00:00 https://biolegacyresearch.com/nitrosamines-guidances-published-by-the-fda-and-ema/ 2023-08-04T19:00:26+00:00 https://biolegacyresearch.com/regulatory-update-week-of-aug-7-2023/ 2023-08-04T19:15:00+00:00 https://biolegacyresearch.com/regulatory-update-week-of-july-31-2023/ 2023-08-04T19:15:00+00:00 https://biolegacyresearch.com/medicare-coverage-for-novel-technologies-slow-and-lacking-say-stanford-researchers/ 2023-08-04T19:35:00+00:00 https://biolegacyresearch.com/legislative-update-week-of-aug-7-2023/ 2023-08-07T18:39:26+00:00 https://biolegacyresearch.com/oncologist-group-blames-rebates-and-discounts-for-cancer-drug-shortages/ 2023-08-07T18:55:34+00:00 https://biolegacyresearch.com/chamber-phrma-supreme-court-brief-supports-manufacturers-in-anti-terrorism-case/ 2023-08-07T18:59:57+00:00 https://biolegacyresearch.com/stryker-launches-ad-campaign-for-robotic-assist-knee-and-hip-replacements/ 2023-08-07T20:31:04+00:00 https://biolegacyresearch.com/quick-notes-on-aug-7-2023/ 2023-08-07T20:46:28+00:00 https://biolegacyresearch.com/wegovy-cuts-heart-attack-stroke-risk-20-in-five-year-trial/ 2023-08-08T18:08:37+00:00 https://biolegacyresearch.com/social-anxiety-disorder-responds-to-vistagens-nasal-spray-in-phase-3-trial/ 2023-08-08T19:15:44+00:00 https://biolegacyresearch.com/merck-partners-with-gingko-bioworks-on-490-million-production-improvement-project/ 2023-08-08T20:58:31+00:00 https://biolegacyresearch.com/lilly-intentionally-botched-math-to-sink-eczema-drug-nektar-suit-alleges/ 2023-08-08T21:06:16+00:00 https://biolegacyresearch.com/industry-objects-to-stacking-requirement-in-medicaid-drug-rebate-rule/ 2023-08-08T21:33:47+00:00 https://biolegacyresearch.com/meeting-planner-week-of-aug-7-2023/ 2023-08-09T19:27:31+00:00 https://biolegacyresearch.com/formycon-fresenius-reach-licensing-agreement-for-stelara-biosimilar/ 2023-08-09T20:26:45+00:00 https://biolegacyresearch.com/device-cybersecurity-patches-are-design-changes/ 2023-08-09T20:33:09+00:00 https://biolegacyresearch.com/texas-settles-vyvanse-medicaid-fraud-allegations-with-takeda-baxter-for-42-million/ 2023-08-09T20:56:51+00:00 https://biolegacyresearch.com/multiple-warning-letters-advance-fdas-fight-against-deg-eg-contamination/ 2023-08-09T22:04:28+00:00 https://biolegacyresearch.com/fda-drug-and-device-approvals-july-to-august-2023/ 2023-08-10T18:15:13+00:00 https://biolegacyresearch.com/novo-nordisk-regeneron-expand-pipelines-with-weight-loss-hearing-acquisitions/ 2023-08-10T18:35:00+00:00 https://biolegacyresearch.com/balance-benefits-risks-of-collecting-diverse-patient-data-post-approval-guidance-says/ 2023-08-10T19:00:33+00:00 https://biolegacyresearch.com/classification-categories-formal-meetings-under-bsufa-iii-explained-in-draft-guidances/ 2023-08-10T19:01:20+00:00 https://biolegacyresearch.com/appeals-court-rules-in-favor-of-axonics-in-ongoing-medtronic-patent-dispute/ 2023-08-10T19:40:50+00:00 https://biolegacyresearch.com/cardiosave-iabp-sees-third-class-i-recall-in-less-than-a-year/ 2023-08-11T17:05:58+00:00 https://biolegacyresearch.com/more-fda-guidance-needed-to-untangle-combination-product-regulations/ 2023-08-11T18:56:26+00:00 https://biolegacyresearch.com/advamed-report-finds-new-resources-critical-for-cms-to-approve-medtech-timely/ 2023-08-11T19:15:00+00:00 https://biolegacyresearch.com/eu-manufacturers-must-step-up-pace-of-applications-for-new-mdr-requirements/ 2023-08-11T19:30:00+00:00 https://biolegacyresearch.com/quick-notes/ 2023-08-11T20:00:04+00:00 https://biolegacyresearch.com/legislative-update-week-of-aug-14-2023/ 2023-08-14T18:10:36+00:00 https://biolegacyresearch.com/a-single-clinical-study-underpinned-most-2022-drug-approvals-study-finds/ 2023-08-14T18:41:59+00:00